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Chair: J. Brian Fowlkes
The goal of targeted drug delivery is the spatial and temporal localization of a
therapeutic agent and its associated bioeffects. One method of drug localization is
acoustic droplet vaporization (ADV), whereby drug-laden perfluorocarbon (PFC)
emulsions are vaporized into gas bubbles using ultrasound, thereby releasing drug
locally. Transpulmonary droplets are converted into bubbles that occlude capillaries,
sequestering the released drug within an organ or tumor. This research investigates
the relationship between the ADV and inertial cavitation (IC) thresholds - relevant
for drug delivery due to the bioffects generated by IC - and explores the delivery of
lipophilic and hydrophilic compounds using PFC double emulsions.
IC can positively and negatively affect ultrasound mediated drug delivery. The
ADV and IC thresholds were determined for various bulk fluid, droplet, and acoustic
parameters. At 3.5 MHz, the ADV threshold occurred at a lower rarefactional
pressure than the IC threshold. The results suggest that ADV is a distinct
xxi
phenomenon from IC, the ADV nucleus is internal to the droplet, and the IC nucleus
is the bubble generated by ADV.
The ADV triggered release of a lipophilic chemotherapeutic agent, chlorambucil
(CHL), from a PFC-in-oil-in-water emulsion was explored using plated cells. Cells
exposed to a CHL-loaded emulsion, without ADV, displayed 44% less growth
inhibition than cells exposed to an equal concentration of CHL in solution. Upon
ADV of the CHL-loaded emulsion, the growth inhibition increased to the same level
as cells exposed to CHL in solution.
A triblock copolymer was synthesized which enabled the formulation of stable
water-in-PFC-in-water (W1/PFC/W2) emulsions. The encapsulation of fluorescein
in the W1 phase significantly decreased the mass flux of fluorescein; ADV was shown
to completely release the fluorescein from the emulsions. ADV was also shown to
release thrombin, dissolved in the W1 phase, which could be used in vivo to extend
synergistically the duration of ADV-generated, microbubble-based embolizations.
Overall, the results suggest that PFC double emulsions can be used as an
ultrasound-triggered drug delivery system. Compared to traditional drug delivery
systems, ADV could be used to increase the therapeutic efficacy and decrease the




1.1 The Magic Bullet
In 1908, the German scientist, Paul Ehrlich - who coined the term chemotherapy
- received the Nobel Prize for Physiology or Medicine based on his landmark insights
in the field of immunology. Earlier in his career, Ehrlich observed that certain
histological dyes selectively concentrated in specific biological structures, which
caused him to postulate that such specificity could be used therapeutically [1].
Additionally, based on his seminal studies in immunology, Ehrlich hypothesized that
antigens were recognized via their binding of side chains, later termed receptors,
associated with cells [2]. These findings caused Ehrlich to develop the concept of a
magic bullet - a chemical agent that possesses a high affinity to the causative agent
of disease [3]. Thus, the vision of magic bullets form the basis of modern, targeted
medicine and its seemingly simplistic yet challenging goal: treating pathogens or
diseased tissue while remaining systemically harmless.
Despite the passage of more than a century since Ehrlich’s magic bullet concept,
the development of therapeutic agents that behave as magic bullets has been
confounded by the biochemical and physiological complexity of the human body.
Arguably, most disease states do not possess a magic bullet. The focus of this
dissertation is the development of one type of technology - liquid droplets activated
with ultrasound (US) - that may have the potential to be a magic bullet for multiple
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diseases. This chapter presents an overview of targeted drug delivery, including
the use of US and colloids in modulated (i.e. externally controlled) delivery. The
proposed drug delivery mechanism, acoustic droplet vaporization (ADV), will also
be presented.
1.2 An Overview of Targeted Drug Delivery
The paradigm of targeted drug delivery is the localization and subsequent
action of a therapeutic agent only at the target within a suitable time window.
The target is defined as a level of biological structure such as an organ or tissue
type, a specific cell type within an organ or tissue, or an intracellular compartment
within a specific cell type [4]. Comparatively, traditional drug delivery systems -
such as immediate release capsules or intravenous infusions - which still form the
predominant administration routes of drugs, are unable to effectively control the rate
of drug delivery or the target area of administration. With these traditional delivery
systems, non-selective drug uptake occurs by cells, tissues, or organs throughout the
body due to the lack of spatial and temporal selectivity of the administered drug.
Targeted delivery systems provide numerous advantages over traditional systems
including: use of less total drug, reduction in local or systemic side effects, increase
in bioavailability for some drugs, and improvement in treatment efficiency. These
advantages are especially important in the clinical use of drugs that possess a low
therapeutic index (TI 1), which is defined in Eq. 1.1 as the ratio of the lethal dose
required to kill 50% of the population, LD50, to the the effective (i.e. therapeutic)
dose for 50% of the population, ED50. The TI of a drug is not completely dependent
on its inherent physiochemical properties but also a function of the manner in which
the drug is formulated (ex. solution versus emulsion) and thus presented to the body







The notion that that the presentation of a drug contributes to its performance
evolved during the 1960s [6] and contrasted with the historical role that drug
delivery systems and formulations were relegated to: a “do no harm” capacity [7].
Many of the initial targeted delivery strategies included implantable macroscopic or
microscopic devices that released drugs via zero order kinetics (i.e. constant rate).
Some examples, both manufactured by the Alza Corporation, include Progestasert,
an intrauterine device that releases progesterone, and Ocusert, an ophthalmic insert
that releases the anti-glaucoma drug pilocarpine. Additionally, one of the most
obvious ways of achieving targeted delivery is the direct administration of drugs into
an organ or tissue. Examples include the intra-articular injection of hyaluronic acid
for the treatment of knee osteoarthritis [8] or the hepatic arterial administration of
chemotherapy agents in the treatment of hepatocellular carcinoma [9; 10]. However,
the implantation of a drug delivery device or the at-site administration of a drug is
both invasive and impractical in the treatments of disease states which are deeply
situated in the body or dispersed in nature (ex. highly metastatic cancer).
1.2.1 Pharmaceutical Approaches
Three pharmaceutical strategies have been used in targeted drug delivery: site
specific drug molecules, therapeutic agents that are activated at the target site (i.e.
prodrugs), or the use of carrier systems that direct the drug to the target [11]. The
first strategy is largely dependent on the upregulation or downregulation of specific
proteins, genes, or signaling molecules that are involved in pathogenesis. Identifying
drug-like molecules that selectively interact with the molecular cause of a disease, if
known, is only part of this strategy. High molecular affinity and specificity does not
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necessarily translate into a molecule that will possess appropriate physiochemical
properties such that the molecule can be readily absorbed, escape extensive hepatic
metabolism, distribute sufficiently in the target tissue, and avoid rapid excretion.
Examples of these site-specific molecules in the area of chemotherapeutics are listed
in Table 1.1.
Table 1.1: Examples of clinically-used, targeted chemotherapy agents
Compound Tradename Company Structure Target
Bevacuzimab Avastin Genentech/Roche monoclonal vascular endothelial
antibody growth factor A
Imatinib Gleevac Novartis small receptor tyrosine
molecule kinase
Sunitinib Sutent Pfizer small receptor tyrosine
molecule kinase
Trastuzumab Herceptin Genentech monoclonal human epidermal growth
antibody factor receptor 2
The second strategy - prodrugs - can be used to overcome physiochemical (e.g.
solubility, chemical instability) or biopharmaceutical problems (e.g. bioavailability,
toxicity) associated with the active form of a drug [12]. An example of this
is L-3,4-dihydroxyphenylalanine (L-DOPA), the prodrug of the neurotrasmitter
dopamine; in this case, L-DOPA can cross the blood-brain barrier, unlike dopamine,
where it is then converted into dopamine in the corpus striatum. The efficacy of a
prodrug approach is dependent on the ability of the prodrug to access the target
receptor and the specificity of the activating mechanism, usually an enzyme such as
an esterase or amidase, at the target. Additional activation mechanisms utilized in
targeted delivery of anticancer prodrugs include low extracellular pH and hypoxia
within the tumor core [13].
The third strategy - carrier systems - is based on the physical inclusion or
chemical attachment of a drug to a carrier. Due to the association between the
drug and the carrier, the distribution of the drug is governed by the physiochemical
properties of the carrier, not the drug. Carrier-based systems can be divided
into two main categories: soluble macromolecules and particulates. The former
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includes conjugating drugs to proteins (e.g. antibodies, albumin, glycoproteins),
genetic material, or polymers (e.g. dextran, N-(2-hydroxypropyl)methacrylamide).
An example is gemtuzumab ozogamicin (Mylotarg, Wyeth), a conjugate of a
recombinant humanized monoclonal antibody and calicheamicin, which is used in
the treatment of acute myelogenous leukemia. The cytotoxic antibiotic portion of
the conjugate (calicheamicin) is targeted to CD33, a surface glycoprotein expressed
on myeloid leukemia cells, via the antibody. Particulate-based carriers include
colloids, liposomes, lipoproteins, niosomes, and activated carbon as well as cells
(ex. erythrocytes, leukocytes, platelets, fibroblasts, and hepatocytes) . Colloids,
specifically emulsions, were used in this work and will be discussed in a latter section.
1.2.2 Ultrasound Modulated Systems
An alternative approach for targeted drug delivery is the use of devices or delivery
systems that release drugs in response to an external stimulus. These stimuli include
magnetism [14], electricity [15], light [16], temperature [17], pH [18], or ultrasound
- the focus of this work and discussed subsequently. The goal of stimulus-based
delivery is to increase the spatial and temporal selectivity of drug delivery. Rather
than the zero order kinetics desired by the initial developers of drug delivery systems,
stimulus-triggered delivery enables the delivery of drug when or where the body
needs it. In many cases, stimulus-based delivery builds upon the previously described
pharmaceutical approaches to targeted drug delivery. Stimulus-based systems can
be considered either open or closed-loop control systems depending on whether the
rate of drug delivery is automatically adjusted based on a measured variable, such
as pH [19].
Ultrasound (US) is widely used in the field of medicine both diagnostically and
therapeutically. US is especially suited for drug delivery since it can be non-invasively
transmitted and focused onto deeply located sites within the body with millimeter
precision. There are three types of US-triggered delivery: device or depot enhanced
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delivery, sonophoresis, and colloidal based delivery. The former two will be discussed
here while the last type will be highlighted in the next section.
The first method, device or depot enhanced delivery, utilizes US to increase
the release rate of a drug that is embedded into a polymer matrix. When exposed
to US (75 kHz, 50% duty cycle, 5 W/cm2), the release rates of p-nitroaniline,
p-aminohippuric acid, bovine serum albumin, and insulin were shown to dramatically
increase, in a reversible manner, from both bioerodible and nonerodible matrices
[20]. Similar results were obtained when polymer matrices, containing insulin, were
implanted into diabetic rats and then exposed to US (1 MHz, 5 W/cm2) for 30
minutes; a dramatic decrease in blood glucose level, post US exposure, was observed
[21]. In depot-enhanced delivery, acoustic cavitation is the main mechanism driving
the matrix degradation and increase in drug release, similar to thrombolysis using
pulsed US [22].
The second method, sonophoresis (phonophoresis), utilizes US to increase the
transdermal delivery of therapeutic agents applied to the skin. Similar to other
transdermal drug delivery applications, sonophoresis bypasses first-pass hepatic
metabolism, thereby increasing the therapeutic efficacy of the applied drug. Recent
comprehensive reviews [23; 24] detail the types of drugs used in in vitro and in vivo
sonophoretic studies. Clinical studies with three non-steroidal anti-inflammatory
drugs - diclofenac [25], ibuprofen [26], and ketoprofen [27] - demonstrate the efficacy
of sonophoresis with 1 MHz US. Overall, low frequency US (20-100 kHz) enhances
transdermal drug transport 1000 times more than high frequency US (1-3 MHz)
[28; 29]. This difference is due to the increased likelihood of inertial cavitation, one
of the driving mechanisms, at lower frequencies. Inertial cavitation is hypothesized
to generate bilayer disordering within the stratum corneum, the major barrier to
transdermal drug delivery. The next section will discuss colloids used in US-triggered
drug delivery.
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1.3 Colloids used in Diagnostic and Therapeutic
Ultrasound
A colloid is a type of dispersed system where an internal (dispersed) phase
is distributed within an external (continuous) phase. Common examples of
colloids utilized in pharmaceutical formulations include emulsions (liquid-in-liquid),
suspensions (solid-in-liquid), foams or microbubbles (gas-in-liquid), and aerosols
(either liquid-in-gas or solid-in-gas). Colloidal particles range in diameter from
approximately 1 nm to 1 µm. Larger particles (diameters > 1 µm) can generally be
considered colloidal, especially in cases where the dispersed system is heterogeneous
in particle size. In order to minimize the surface energy of the particles, surfactants
are used to reduce the interfacial tension in the colloid, especially for emulsions or
microbubbles, thereby stabilizing the particles from phase separation. Compared to a
solid formulation (i.e. tablet, capsule), the surface area of a colloid is typically much
larger, due to the small particle size, thereby leading to a higher dissolution rate and
a potential increase in bioavailability of a colloidal drug formulation. Additionally,
drugs that are insoluble in aqueous media can be formulated as colloids. Two types
of US-activated colloids - microbubbles and emulsions - will be discussed next.
1.3.1 Microbubble Agents
First published by Gramiak and Shah in 1968 [30], the most commonly utilized
colloids in medical US applications are microbubble-based contrast agents, which
are approved for clinical, diagnostic use. Upon intravascular administration, these
compressible blood pool agents increase the scattering and reflection of US waves
by several orders of magnitude relative to blood. In order for microbubbles to be
clinically useful in diagnostic US imaging, the contrast agent must not dissolve
too quickly due to gas diffusion enhanced by the Laplace and arterial pressures.
Thus, as can be seen in Table 1.2, contrast agent formulations evolved over various
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generations in an effort to maximize their utility. First generation contrast agents,
essentially air bubbles, are not surfactant stabilized and therefore only persist for
seconds upon injection. Additionally, these first generation agents are too large to
pass through capillaries and thus are used primarily in imaging the left side of the
heart [31]. Second generation agents, transcapillary in size, are stabilized by a shell
(2 to 500 nm thick) of protein, lipid, or polymer that enables the microbubbles to
persist for up to 5 minutes after injection. The stability afforded by the shell can
be explained in terms of the Laplace equation (Eq. 1.2), where ∆P is the pressure
difference between the inside (Pi) and outside (Po) of a bubble of radius r in a liquid
with surface tension σ. The shell reduces the surface tension which reduces the
pressure inside the bubble and thus increases the microbubble lifespan. Furthermore,
the shell provides a resistance to gas permeation into or out of the microbubble [32].




Table 1.2: Three generations of US contrast agents
Generation Gas core Shell Example(s)
First Air None Echovist (Schering AG)
Second Air Protein, polymer, Levovist (Schering AG)
or lipid Albunex (Molecular Biosystems)
Third C3F8, C4F10, C5F12 Protein, polymer, Optison (GE Healthcare)
C6F14, SF6 or lipid Definity (Bristol-Myers Squibb)
Additionally, Eq. 1.2 highlights the importance of the shell in stabilizing the
microbubble as the radius decreases. Besides hindering microbubble gas loss,
dissolution, and coalescence, the shell enables the formation of more controlled size
distributions [33]. The shell composition can affect how resistant the microbubbles
are to rupture when exposed to US and hydrodynamic conditions in vivo. For
example, lipid shells (1 to 2 nm thick) are highly compliant, rendering lipid-coated
microbubbles more stable than those possessing relatively rigid albumin shells (10
to 15 nm thick) [34]. The shell can also be modified to contain polyethylene glycol
8
(PEG), thereby masking the contrast agent from the immune system, or targeting
ligands - cell membrane receptor antibodies, peptides, or small molecules - which
enables active targeting of microbubbles [35; 36]. Third generation agents, also shell
stabilized, contain gases whose solubilities in blood and diffusion coefficients are
significantly less than air. The use of inert, higher molecular weight gases, such as
perfluorocarbons (PFCs), prolong the lifespan of microbubbles upon injection. For
example, using the modified Epstein-Plesset equation [32; 37], a 5 µm diameter,
lipid-coated bubble is predicted to exist for 1 second if the gas core consists of air
versus 105 seconds (27.8 hrs) if the microbubble contains perfluorobutane [38]. In
reality, third generation agents persist longer in the circulation (> 5 min), though
not nearly the lifespan predicted by the aforementioned model which does not
account for flow dynamics.
The use of microbubbles in targeted drug delivery is attractive due to
the possibility of combining diagnostic feedback with therapy and relies upon
the interaction between microbubbles and US. The resonance frequency of
transpulmonary bubbles fortuitously lies in the medical imaging frequency range.
Microbubbles can also oscillate in a nonlinear manner when insonified and
microbubble destruction can occur at higher amplitude US. Acting as cavitation
nuclei, microbubbles can generate microstream swirling, micro-jetting, and
hydrodynamic shock waves during oscillations [39] that can cause bioeffects such
as cellular erosion or lysis, molecular degradation, and free radical formation [40].
Alternatively, these bioeffects can be used in the enhancement of drug delivery via
sonoporation, whereby insonifed microbubbles adjacent to cells create a transient
increase in membranes permeability. The pores generated during this process range
in size from 30 to 100 nm up to a few microns and reseal over the span of seconds
or minutes [41]. Thus contrast agent destruction can be used as an adjuvant for
therapeutic agents not coupled to microbubbles. This is clearly seen in an in
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vitro study where increased uptake of plasmids coding for green fluorescent protein
occurred as a result of sonoporation [42].
Despite the benefits of co-administering microbubbles and therapeutic agents,
there are distinct advantages of incorporating the agents within the microbubbles
such as: localizing the effect of the agent at the insonation site, reducing the required
dose of agent, and improving the therapeutic efficacy of the agent when dosed in a
colloidal formulation. The incorporation of the drug or gene is typically accomplished
using one of the following methods (Fig. 1.1): attachment (covalent or non-covalent)
to the shell either directly or using a secondary carrier, such as a liposome or
nanoparticle [43; 44]; intercalation within the shell [45; 46]; or incorporation within
a fluid inside the shell. With the last technique, it is possible to include either an oil
[47; 48] or aqueous layer within the microbubble [49].
PFC gas 
Direct coupling  
to shell 





within liquid layer 
Lipid shell 
Figure 1.1: Drug loading strategies for a lipid-coated, PFC microbubble.
1.3.2 Perfluorocarbon Emulsions
Similar to PFC microbubbles, PFC emulsions (i.e. PFC-in-water) are being
studied in diagnostic and therapeutic US applications as well as for in vivo oxygen
delivery (blood substitutes) [50]. The latter application, in vivo oxygen delivery,
utilizes higher molecular weight (i.e. higher boiling point) PFCs than the former
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US applications, which is the focus of this work. PFCs possess ideal properties
for biomedical applications, such as inertness and biocompatibility, and unique
properties (hydrophobicity, lipophobicity, and high gas solubility) stemming from the
carbon-fluorine bonds within the molecules [51]. Compared to PFC microbubbles,
PFC emulsions possess a longer circulation half-life [52] and a larger payload fraction.
Emulsions, however, are less echogenic than microbubbles, as can be seen in Eq.
1.3 (Born approximation) where Σs is the scattering cross section of a particle, r is
the particle radius, k is the wave number, κs is the particle compressibility, κ is the
medium compressibility, ρs is the particle density, and ρ is the medium density [53].
Thus, the scattering cross section of a droplet is less than that of an equally sized
microbubble, even without including the mechanical resonance of a microbubble, due
















In early US studies, liquid PFC - perfluoroctylbromide (PFOB) - was administered
orally as a diagnostic contrast medium for gastroenterography [54]. Later, PFOB
was formulated as an emulsion for intravascular injection during US imaging of
rabbit livers in vivo [55]. Sonus Pharmaceuticals developed EchoGen, an US contrast
agent consisting of a perfluoropentane (PFP) emulsion. Upon injection into the
body (37◦C), the PFP (29◦C boiling point) droplets vaporized into microbubbles;
subsequently, it was published that hypobaric activation of the emulsion prior to
injection yielded more microbubbles than thermal activation alone [56]. Contrast
studies with perfluorohexane (PFH) emulsions have shown that US can be used
to monitor the uptake of the droplets by macrophages [57]. PFP emulsions have
also been used as cavitation nucleation agents, which can promote in vivo gene
transfer during shock wave lithotripsy [58; 59]. Additionally, nanoemulsions using
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perfluorodichlorooctane (PFDCO) or PFOB have been formulated for contrast
studies [60; 61]. These PFC emulsions can extravasate in the microvasculature
of tumors, though the echogenicity of these colloids, relative to micron-sized
PFC emulsions, is less since the scattering cross section scales according to sixth
power of the particle radius (Eq. 1.3). However, the layering or accumulation of
PFC nanodroplets, which can form a specular reflector, can increase the acoustic
reflectivity (i.e. echogenicity) of the nanoemulsion [52].
1.3.3 Acoustic Droplet Vaporization
US triggered drug delivery can occur from PFC emulsions via a process known as
acoustic droplet vaporization (ADV). ADV is a mechanism whereby an emulsion is
converted into gas bubbles using ultrasound. The dispersed phase of the emulsion,
typically a PFC, is usually superheated, meaning that the dispersed phase is a liquid
that exists at a temperature and pressure corresponding to the vapor region in the
phase diagram. The origin of ADV can be traced to Donald Glaser’s development of
the bubble chamber that was filled with a superheated liquid and used extensively
in radiation dosimetry [62]. The passage of ionizing radiation through the chamber
causes vaporization of the superheated fluid, which can be observed as tracks of
bubbles. This is analogous to the cloud (Wilson) chamber, filled with a supercooled
vapor, developed in 1911-1912 [63]; in this case, the passage of ionizing radiation
through the chamber causes tracks of condensation in the supercooled vapor. For
both chambers, the metastable state is fragile and relatively short-lived due to the
high number of potential nucleation sites within the medium.
In 1979, Robert Apfel described a new type of radiation dosimeter - a superheated
drop detector (SDD) - which was obtained by emulsifying a superheated fluid with an
immiscible fluid, thereby fractionating the superheated fluid into many subdivisions
[64]. This fractionation ensures that some droplets are free of nucleating impurities
and that triggering of one droplet by radiation would not trigger all of the droplets.
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Additionally, unlike a bubble chamber which is only transiently superheated upon
a decrease in chamber pressure, a SDD is constantly superheated, thereby making
the latter constantly sensitive to radiation. Apfel patented the SDD technology in
1998 [65] for use in three proposed applications: diagnostic contrast agent, vascular
occlusion, and localized drug delivery; the sensitivity of the SDD to acoustic radiation
(i.e. ultrasound) was also described in the patent. Kripfgans et al., who termed the
ADV acronym, demonstrated the feasibility of using medically relevant ultrasound to
produce ADV with micron-sized emulsions [66]. The physical mechanisms governing
the ADV process are not as well understood as the interaction between microbubbles
and US. However, published works delve into the effects of acoustic, emulsion, and
bulk fluid properties on the ADV process, specifically the ADV threshold [66–73].
Additionally, a theoretical model explores the effect of droplet size, gas nucleus size,
bulk fluid viscosity, and bulk fluid surface tension on bubble growth during ADV
[74].
ADV has been studied in four applications: aberration correction [75; 76],
occlusion therapy [74; 75; 77–81], microbubble-enhanced high intensity focused US
[82–84], and drug delivery. Table 1.3 lists publications focused on ADV-triggered drug
delivery. Due to the hydrophobicity and lipophobicity of the dispersed PFC phase,
similar formulation approaches, which were described previously for microbubbles,
are utilized for PFC emulsions. Thus upon ADV, each drug-laden droplet will release
its therapeutic payload when the PFC phase is vaporized. The procedure would be
minimally invasive since the emulsion would be administered intravenously, and the
US would be applied transcutaneously. Additionally, ADV-triggered delivery can be
potentially coupled to other ADV-induced phenomenon, such as vascular occlusion,
to produce therapeutic synergisms.
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Table 1.3: Published drug delivery studies using ADV
Reference Drug PFC
Fang et al. 2007 [85] resveratrol PFP, PFH
Rapoport et al. 2007 [86] doxorubicin PFP
Fang et al. 2009 [87] camptothecin PFP, PFH
Hwang et al. 2009 [88] apomorphine PFP
Rapoport et al. 2009, 2010 [89–91] paclitaxel PFP
Fabiilli et al. 2010 [67] chlorambucil PFP
Fabiilli et al. 2010 [92] fluorescein/thrombin PFP, PFH
1.4 Overview of Dissertation
The following chapters will explore ADV and its use in drug delivery using
micron-sized PFC emulsions. Each chapter contains an introductory section thereby
providing the necessary background material so that each chapter can be read
independently. A detailed outline of the dissertation is described below.
Chapter II investigates the relationship between ADV and inertial cavitation
(IC), specifically the thresholds of each, possibly interrelated, phenomenon. This
work was motivated by previous studies that focused on elucidating the mechanisms
involved in ADV [68; 70; 72; 75]. IC, which occurs when a bubble is exposed
to US above a certain threshold, can produce phenomena such as extravasation,
sonoporation, or molecular degradation that could potentially affect ADV-triggered
drug delivery. It was determined - for various bulk fluid, droplet, and acoustic
properties - that the ADV threshold occurred at a lower rarefactional pressure than
the IC threshold. Thus, ADV appears to be a mechanism that is separable from IC.
Appropriate citations for material in this chapter include:
• M.L. Fabiilli, K.J. Haworth, O.D. Kripfgans, P.L. Carson, and J.B. Fowlkes.
“The role of inertial cavitation in acoustic droplet vaporization.” Proceedings
of the IEEE International Ultrasonics Symposium, pp. 768-771, 2008.
• M.L. Fabiilli, K.J. Haworth, N.H. Fakhri, O.D. Kripfgans, P.L. Carson, and
J.B. Fowlkes, “The role of inertial cavitation in acoustic droplet vaporization.”
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IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol.
56, no. 5, pp. 1006-1017, 2009.
Chapter III provides a proof-of-concept study for drug delivery using ADV.
A double emulsion (PFC-in-oil-in-water) containing chlorambucil, a lipophilic
chemotherapy agent, was formulated. The ability of ADV to selectively release
chlorambucil from the emulsion was tested in a plated cell model by measuring the
growth inhibition of Chinese hamster ovary cells. The ADV threshold of the double
emulsion and the ADV efficiency - the fraction of droplets that vaporize - were
measured as a function of droplet diameter. Appropriate citations for material in
this chapter include:
• M.L. Fabiilli, I.E. Sebastian, K.J. Haworth, O.D. Kripfgans, P.L. Carson,
and J.B. Fowlkes. “Ultrasonic delivery of a chemotherapeutic agent using
acoustic droplet vaporization (ADV).” Proceedings of the IEEE International
Ultrasonics Symposium, 2009.
• M.L. Fabiilli, I.E. Sebastian, and J.B. Fowlkes. “Development of an acoustic
droplet vaporization, ultrasound drug delivery emulsion.” Proceedings of the
International Symposium on Therapeutic Ultrasound, pp. 295-298, 2009.
• M.L. Fabiilli, K.J. Haworth, I.E. Sebastian, O.D. Kripfgans, P.L. Carson,
and J.B. Fowkles. “Delivery of chlorambucil using acoustically-triggered,
perfluoropentane emulsions.” Ultrasound in Medicine and Biology, vol. 36, no.
8, pp. 1364-1375, 2010.
Chapter IV describes the development of double emulsions that can contain
a water-soluble therapeutic agent (water-in-PFC-in-water). Previous to the work
described in chapter IV, other ADV-triggered drug delivery studies focused on the
delivery of lipophilic compounds. ADV was shown to significantly increase the
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mass flux of fluorescein, encapsulated within the emulsions, compared to conditions
without ADV. Additionally, emulsions containing thrombin were formulated, which
could be potentially used to increase the duration of ADV-generated embolizations.
ADV was shown to decrease the clotting time of blood in vitro, indicating the release
of thrombin via ADV. Appropriate citations for material in this chapter include:
• M.L. Fabiilli, J.A. Lee, O.D. Kripfgans, P.L. Carson, and J.B. Fowlkes.
“Ultrasonically-activatable, perfluorocarbon double emulsions containing
an aqueous payload for drug delivery.” Proceedings of the International
Symposium on Therapeutic Ultrasound, 2010.
• M.L. Fabiilli, J.A. Lee, O.D. Kripfgans, P.L. Carson, and J.B. Fowlkes.
“The release of thrombin, using acoustic droplet vaporization (ADV), from
perfluoropentane double emulsions.” Proceedings of the IEEE International
Ultrasonics Symposium, 2010.
• M.L. Fabiilli, J.A. Lee, O.D. Kripfgans, P.L. Carson, and J.B. Fowlkes.
“Delivery of water-soluble drugs using acoustically-triggered, perfluorocarbon
double emulsions.” Pharmaceutical Research, accepted September 2010.
Chapter V provides a summary of results described in the previous chapters.
Based on the completed work, future studies are presented which could further the
development of ADV-triggered drug delivery.
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CHAPTER II
The Role of Intertial Cavitation in Acoustic
Droplet Vaporization
2.1 Introduction
Emulsions containing micron and nanometer-sized perfluorocarbon (PFC)
droplets are being studied in diagnostic and therapeutic applications of ultrasound
(US). For example, the use of PFC nanodroplets has been explored in US molecular
imaging and the targeted delivery of therapeutic agents [1–4]. Another research area
is acoustic droplet vaporization (ADV), where a superheated, micron-sized liquid
droplet - stabilized by a surfactant shell - is phase-transitioned into a gas bubble
using US. The superheated liquid is a straight-chain PFC, which belongs to a class
of compounds that are inert, hydrophobic, lipophobic, and biocompatible [5]. The
therapeutic potentials of ADV were described by Apfel [6] and Kripfgans et al. [7]
in applications such as embolotherapy and drug delivery. Additional applications of
ADV include its use in phase aberration correction [8; 9].
Micron-sized PFC droplets can be systemically administered - either intra-
arterially or intravenously - and greater than 95% (by number) of the droplets are
small enough to pass through capillaries without producing obstructions [10]. Upon
ADV, the generated bubbles grow to typically five to six times that of the original
droplet diameter [7]. Therefore, upon vaporization, the bubbles can become lodged
within capillaries, thus selectively occluding blood flow to targeted tissues or organs.
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The use of ADV in occlusion therapy has been successfully demonstrated in vivo in
canine [8] and lepus [11] models to reduce cerebral and renal perfusion, respectively.
The in vitro ADV of nanometer-sized PFC droplets has also been demonstrated [12].
The physical mechanisms involved in ADV are not clearly understood. The
optimization of ADV for therapeutic applications can be potentially enhanced by
elucidating the mechanisms involved in the ADV process. One proposed mechanism
is acoustic cavitation, which can be defined as the creation, growth, and/or collapse
of a bubble or cavity within a fluid when the fluid is exposed to an acoustic pressure
field [13]. It has been found that the tensile strength of a liquid is much lower than
the theoretical tensile strength due to the presence of cavitation nuclei within the
fluid [14]. Two general types of cavitation exist - stable and inertial [15] - although
there has been considerable debate about the terminology used. Stable cavitation
is the oscillation, both linear or non-linear, of a bubble about an equilibrium size.
The oscillation can continue for many cycles of acoustic pressure. Inertial cavitation
(IC) occurs when the bubble diameter grows to at least twice its original diameter,
generally during a single cycle of acoustic pressure [13]. The bubble then collapses
violently, driven by the inertia of the fluid, potentially fragmenting into many
smaller bubbles. Such cavitation can occur repetitively and even within a single
bubble. The bioeffects of IC, which stem from the generated high temperatures,
pressures, and velocities (i.e. shock wave and liquid jet formation), include cellular
erosion or lysis, molecular degradation, and the formation of free radicals [15; 16].
In the case of embolotherapy, the minimization of these bioeffects may be important
to prevent the extravasation of blood components, which could reduce the efficacy
of ADV-induced embolotherapy. Alternatively, these bioeffects could enhance drug
delivery via sonoporation, as highlighted in a recent review [17].
The cavitation process is started by nucleation, either within the fluid itself due
to thermal motion, termed homogeneous, or at a boundary between the fluid and
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another surface, termed heterogeneous. In most practical situations, heterogeneous
nucleation is more common since homogeneous nucleation tends to require higher
rarefactional pressures. However, the body contains few, if any, cavitation nuclei that
can be activated by diagnostic US pulses [18], and the probability of homogenous
nucleation within the body using diagnostic US is expected to be rare [19]. Therefore,
the introduction of materials within the body, such as microbubbles or droplets, may
serve as cavitation nuclei depending on the rarefactional pressure levels of applied
diagnostic or therapeutic US. Hence, the mechanical index (MI) is used as a metric
to determine the susceptibility of IC with diagnostic US scanners.
The nucleation of ADV can occur in three regions: within the droplet core (i.e.
PFC phase); adjacent to the surfactant shell (either inside or outside of the droplet);
and external to the droplet within the bulk fluid phase. Previous work demonstrated
that the ADV threshold at 1.44 MHz decreased when US contrast agent was present
with the droplets [20]. In this case, it was surmised that the microbubbles acted
as cavitation nuclei external to the droplet. Counter to this however, micrographs,
taken using a high-speed camera, of single droplets undergoing ADV indicate that
the nucleation location is within the imaged cross section of the droplet, when using
transducers in the 3 to 10 MHz range with microsecond pulse lengths [21].
A previous study measured the in vitro, IC threshold of micron-sized PFC
droplets as a function of droplet composition and US parameters [22]. This study
investigates the relationship between ADV and IC, specifically the necessity of IC
for ADV to occur, and adds insight into the location of ADV nucleation. The
threshold pressures required to induce ADV and IC are simultaneously determined
in an in vitro setup. The materials and methods, including ADV and IC threshold
determination, utilized in this study are described in Section 2.2. Parameters
that are known to influence both thresholds - bulk fluid properties such as gas
saturation, temperature, viscosity, and surface tension; droplet parameters such
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as degree of superheat, surfactant type, and size; and acoustic properties such as
pulse repetition frequency and pulse width - are investigated with the intent of
determining experimental conditions that yield ADV without IC and ADV with IC.
These results are presented and discussed in Section 2.3, with a focus on connecting
the experimental results with possible mechanisms involved in ADV. Section 2.4
describes conclusions concerning the ADV mechanism that are supported by the
results in Section 2.3, as well as discussing similarities between the observed trends
for the ADV and IC thresholds.
2.2 Materials and Methods
2.2.1 PFC Droplets
Albumin droplets were prepared according to a method established by Kripfgans
et al. [7]. Briefly, 750 µL of 4 mg/mL bovine albumin (Sigma-Aldrich, St. Louis,
MO, USA) in normal saline (0.9% w/v, Hospira Inc., Lake Forest, IL, USA) was
added to a 2 mL glass vial (Shamrock Glass, Seaford, DE, USA). Liquid PFC - either
perfluoro-n-pentane (C5F12, Alfa Aesar, Ward Hill, MA, USA), perfluoro-n-hexane
(C6F14, SynQuest Labs Inc., Alachua, FL, USA), or perfluoro-n-octane (C8F18, Alfa
Aesar) - was added gravimetrically to produce a final PFC volume fraction of 25%.
Table 2.1 lists the different PFC core materials that were tested. The vial was sealed
with a rubber stopper (Shamrock Glass) and metal cap (Shamrock Glass). The vial
was then shaken for 45 seconds at 4550 cycles per minute using an amalgamator
(VialMix, Lantheus Medical Imaging, Billerica, MA, USA).
Lipid droplets were made in a similar manner using 750 µL of a lipid blend
rather than albumin. The blend consisted of 5 mg/mL 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC, Avanti Polar Lipids, Alabaster, AL, USA) and 0.2 mg/mL
1,2-dipalmitoyl-sn-glycero-3-phosphate monosodium salt (DPPA, Avanti Polar
Lipids) dissolved in propylene glycol (Acros Organics, Morris Plains, NJ, USA),
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Table 2.1: Boiling points (Tb) of PFCs used to make emulsions and average droplet
diameters, including standard deviations of the means, of the resulting emulsions.
The emulsions were sized one day after their formulation so no significant Ostwald
ripening has occurred. The average number density, including the standard deviation
of the mean, is listed for the undiluted emulsions.
Tb Mean diameter Mean number densityName Formula CAS # Abbreviation
(◦C) (µm) (×109, number per mL)
Perfluoro-n-pentane C5F12 678-26-2 PFP 29 2.09 ± 0.02 4.28 ± 0.05
Perfluoro-n-hexane C6F14 355-42-0 PFH 56 2.20 ± 0.06 3.51 ± 0.20
Perfluoro-n-octane C8F18 307-34-6 PFO 100 2.63 ± 0.04 4.20 ± 0.30
which was heated to 50◦C. The resulting solution was then diluted with an equal
volume of an 8:1 volumetric ratio of normal saline to glycerol (Sigma Aldrich) to
produce the final lipid blend. PFC was then added gravimetrically and the vial
sealed and shaken in the same manner as the albumin droplets.
The shaken vials were refrigerated (5◦C) overnight prior to use. A droplet
pre-dilution, used for sizing and flow tube experiments, was made by diluting 1
vial of droplets to 10 mL with normal saline that had been filtered with a syringe
filter (0.22 µm, Millex GV, Millipore Co., Bedford, MA, USA). A Coulter counter
(Multisizer 3, Beckman Coulter Inc., Fullerton, CA, USA) with a 50 µm aperture
was used to determine the number and size of the resulting droplet solutions.
2.2.2 Experimental Setup
All experiments were conducted in a tank (40 × 60 × 27 cm) containing
degassed, deionized water heated to 37◦C (Ex 7, ThermoNESLAB, Newington, NH,
USA), unless otherwise noted. A calibrated 3.5 MHz single-element transducer
(1.9 cm diameter, 3.81 cm focal length, A381S, Panametrics, Olympus NDT Inc.,
Waltham, MA, USA) was focused at the center of dialysis tubing (14.6 mm diameter,
Spectra/Por, Spectrum Laboratories Inc., Laguna Hills, CA, USA), which was used
as a flow tube. A droplet solution, containing approximately 9 × 104 droplets per
milliliter, was prepared by adding 100 µL of the droplet pre-dilution to 500 mL of
degassed, deionized water heated to the same temperature as the tank water, unless
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otherwise noted. The same number density of droplets was used for all trials. By
comparison, the droplet concentration used for previous lepus studies [11], assuming
an average rabbit weight of 2.5 kg and a cardiac output of 250 mL per minute [23],
was 6.4× 105 droplets per mL. The droplet solution was pumped (Masterflex pump
and speed controller, Cole-Parmer, Chicago, IL, USA) at 2 cm·s−1 (average linear
speed in flow tube) against gravity in a recirculated manner from a 500 mL stirred
flask. The single-element transducer was used to generate ADV while cross-sectional
B-mode cineloops were simultaneously collected downstream using a 10 MHz linear
array (L9, GE Healthcare, Milwaukee, WI, USA). Note that the imaging array
is purposefully located downstream of the single-element transducer so that the
imaging acoustics cannot impact the vaporization acoustics. A schematic of the
setup is displayed in Fig. 2.1.
to pump
from pump





















Figure 2.1: Side (left) and top (right) views of the in vitro setup used for measuring
ADV and IC in flow. A 3.5 MHz single element transducer vaporized the flowing
droplets while a 10 MHz linear array recorded cineloops; IC noise was simultaneously
detected using the hydrophone.
Acoustic pulses sent to the single-element transducer were achieved using a
master function generator (33120A, Agilent Technologies, Palo Alto, CA, USA)
gated by a secondary function generator (3314A, Agilent Technologies). The
gated output signal was sent to a power amplifier (60 dB, Model 350, Matec,
Northborough, MA, USA). IC noise was passively detected using an omnidirectional
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hydrophone (ITC-1089D, International Transducer Co., Santa Barbara, CA, USA)
and radiofrequency (RF) segments (n = 100, 10 MHz sampling) were digitized using
an oscilloscope (9314L, LeCroy, Chestnut Ridge, NY, USA), which was triggered
with each transmitted acoustic pulse. A passive acoustic detector was used to detect
IC since it has been demonstrated that an active detector can affect the cavitation
process [24], especially considering the nature of this experiment where droplet
vaporization is triggered acoustically. The gas content of both the tank water and
the recirculated fluid was measured using a blood-gas analyzer (ABL5, Radiometer,
Westlake, OH, USA). All ADV and IC measurements were taken while the fluid
was being recirculated since it was confirmed, using the Coulter counter, that only
a small fraction of the droplets were vaporized over the course of each run due to
the relatively short on-time of the single-element transducer. The flow tube and
pump tubing were thoroughly flushed with degassed, deionized water between runs
to eliminate carryover of any residual droplets or bubbles. A new droplet solution
was prepared for each run. Each run consisted of cycling through a range of acoustic
pressures from the single-element transducer for the combination of parameters being
interrogated for that particular run. By analyzing the range of pressures tested, it
was possible to determine the ADV and IC thresholds (see next section).
2.2.3 ADV and IC Data Analysis
The recorded B-mode images were analyzed for an increase in echogenicity due
to the presence of stable bubbles. The mean echo power (MEP) was computed, as
seen in Eq. 2.1, using MATLAB (The MathWorks, Inc., Natick, MA, USA) from
the decompressed amplitude data of the collected cineloops, where the compression
algorithm used in the US system was reversed. Similar to the mean echo amplitude
(MEA) [7], MEP is the sum of the squared amplitude (A) at pixel (i,j ) for frame










As seen in Fig. 2.2, a circular region of interest, consisting of the entire interior
of the flow tube cross section, was used for the MEP calculations. Each cineloop
(17 Hz frame rate, MI = 0.2) was 10 seconds in duration, with 3 seconds captured
with the single-element transducer off. As seen in Fig. 2.2, each cineloop consisted
of four regions. A differential MEP value, Eq. 2.2, was used in this work so that
any increases in baseline echogenicity due to the interference pattern from the
single-element transducer were accounted for.
∆MEP = MEP4 −MEP2 (2.2)
MEP2 and MEP4 are the mean MEP values of regions 2 and 4, respectively. MEP2
includes the interference from the single-element transducer, but does not contain
ADV-generated bubbles due to the spatial separation between the single-element
transducer and the imaging array. It was confirmed, using polystyrene spheres (1-50
µm or 381 µm, Duke Scientific, Palo Alto, CA, USA) as IC nuclei, without droplets,
that any bubbles produced by IC (detected by the hydrophone as described next) in
the bulk fluid, but not associated with ADV, were not detected by the imaging array
due to their collapse, fragmentation and/or dissolution. The bubble dissolution
model [25] in a static fluid predicts that an air bubble would have to be at least 8
µm in diameter for the bubble to persist long enough to travel from its generation
location (the focus of the single-element transducer) to the imaging plane of the
linear array. Since only gas bubbles produced by ADV are stable or large enough,
versus bubbles produced by the IC of the bulk fluid, MEP is a direct measure of
bubbles produced by ADV.
The presence of IC in the RF segments was determined relative to a baseline
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Figure 2.2: Left: MEP as a function of time for four different regions: US off (region
1); US on but no bubbles in the linear array field of view (FOV) (region 2); US on
and the initial wave of bubbles appears in the linear array FOV, prior to achieving
a steady state (region 3); US on with a steady state number of bubbles in the linear
array FOV (region 4). Right: B-mode frames (compressed intensity scale) of a flow
tube in region 1 (top) and region 4 (bottom). The exterior boundary of the region of
interest used to calculate the MEP is denoted as a white, dashed circle.
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of degassed water, where it was observed that no IC occurred. Figure 2.3 displays
example RF and spectral data for a segment with and without IC. The integrated
Fourier transform (IFT) in the range 5 to 60 kHz was used to differentiate segments
with and without IC. The criterion for a segment containing IC, at a given acoustic
pressure (P ), is given in Eq. 2.3 where IFTcav,P is the IFT of a segment containing
IC at acoustic pressure P , IFTdegas,P is the IFT of the degassed water at acoustic
pressure P , and σ is the standard deviation.



















































Figure 2.3: Left: RF data of a segment with and without IC. Right: Fourier trans-
forms of RF data from left, showing the large spectral differences between a segment
with and without IC. The following conditions were used: degassed water at 37◦C
with albumin-coated PFP droplets, 83 Hz PRF, 13 cycles, and 6.2 MPa.
IFTcav,P ≥ mean(IFTdegas,P ) + 9 · σ(IFTdegas,P ) (2.3)
Nine standard deviations were empirically chosen as a threshold to distinguish
an IC event from the increase in acoustic backscatter due to the presence of droplets
alone. As seen in Fig. 2.4, the calculated IC threshold is directly correlated with
the number of standard deviations used to determine the threshold. However, from
three to nine standard deviations the threshold increases only slightly. The 0.6
MPa increase in the IC threshold as the number of standard deviations is increased
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from one to nine is smaller than the difference between the ADV and IC thresholds
(see Section 2.3). Therefore, nine standard deviations minimizes the probability of
falsely predicting IC at lower rarefactional pressures and reduces the variability of
the calculated IC threshold while maintaining sensitivity to correctly detecting IC
events. The RF data was processed using MATLAB. Each IC data point consists of
the average of three runs with 100 RF lines collected for each run.
Figure 2.4: The effect of varying the number of standard deviations - σ(IFTdegas,P )
- on the calculated peak rarefactional pressure IC threshold. Refer to Eq. 2.3 for
the criterion used to determine the presence of IC in an RF segment. The average
(n = 3) IC thresholds, plotted with the respective standard deviations, are from the
following experimental conditions: degassed water at 37◦C with albumin-coated PFP
droplets, 83 Hz PRF, and 13 cycles.
2.2.4 ADV and IC Threshold Determination
Figure 2.5 displays an example of the normalized MEP and the percent of
segments containing IC, which is the ratio of segments containing an IC event
(defined according to the previous criterion) to the total number of collected
segments, versus the peak rarefactional pressure for a given experimental condition.
The raw MEP data was normalized, vertically shifted by 10−4 and scaled by 105, to
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facilitate display in Fig. 2.5. Two methods have been previously used to determine
the ADV threshold. In the first method [7], the ADV threshold was the peak
rarefactional pressure at the intersection of two line segments fit to the flat baseline
portion and the upward sloping portion of the ADV data (peak rarefactional pressure
versus MEA). In the second method [20], the slope between adjacent points in the
ADV data was calculated. The threshold was defined as the pressure at which this
slope exceeded a certain criterion. This work uses a refined version of the previously
used slope method [20]. The data in each curve was fit to a sigmoid (Eq. 2.4), where
m1 is the maximum y-value, m2 is the minimum y-value, m3 is the x-value at the
midpoint of y, and m4 is the slope at the y-midpoint.
Figure 2.5: Mean (n = 6) normalized MEP and IC data plotted along with the
respective sigmoidal curve fits and standard deviation at each data point. The raw
MEP data was normalized - vertically shifted by 10−4 and scaled by 105 - to facilate
display on this plot. The threshold for each curve is denoted by an asterisk (*). The
following conditions were used: degassed water at 37◦C with albumin-coated PFP
droplets, 83 Hz PRF, and 13 cycles.








The ADV and IC thresholds were defined as the pressures where the slope of the
sigmoidal curve fit exceeded a predefined value (10−4 for raw MEP and 1 for IC).
The predefined values were determined by observing the values of the derivative at
the pressure threshold as determined by the two line intersection approach for a
small subset of data. The predefined value was then applied to all of the data sets.
The sigmoid derivative method was used in general because it is not as susceptible
to variance in the experimental data. The locations of the derivative thresholds for
both the ADV and IC curves are denoted in Fig. 2.5 by asterisks.
2.3 Results and Discussion
2.3.1 Bulk Fluid Parameters
Table 2.2 displays the ADV and IC thresholds for albumin-coated perfluoro-n-
pentane (PFP) droplets in different bulk fluids used. The thresholds in heparinized
whole blood, water, and water-glycerol mixtures were measured to determine the
impact of gas saturation, viscosity, and surface tension. Heparin (Elkins-Sinn Inc.,
Cherry Hill, NJ, USA) was added to whole, canine blood (8 units per mL blood) to
prevent coagulation; the blood was used within 2 hours of withdrawal. The ADV
threshold is lower than the IC threshold for the presented cases (p < 0.001). In the
case of gas saturation, both the ADV (p = 0.7) and the IC (p = 0.4) thresholds were
not statistically different for the degassed and gas saturated conditions. Additionally,
the presence of droplets caused the IC threshold to decrease for the degassed water
condition while the IC threshold was not statistically different (p = 0.1) in the
gas saturated water condition. Increasing the gas saturation of a highly filtered
bulk fluid, containing polystyrene spheres as nuclei, is known to decrease the IC
threshold for heterogeneous nucleation [26]. The rate at which a bubble dissolves
increases as the dissolved gas concentration of the bulk fluid decreases; the dissolved
gas concentration is also known to affect the nucleation threshold [26]. This lack
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of gas saturation dependence on the IC threshold may be explained with three
relevant scenarios. First, the wettability of the albumin surface, adjacent to the
bulk fluid, may be so high that there are few hydrophobic crevices with gas nuclei
present. Second, there are still enough gas nuclei on the droplet exterior, even in
the degassed fluid, to be above the critical concentration of nuclei necessary for IC.
Third, IC occurs only when gas bubbles are present, presumably created via ADV.
Therefore, since the ADV threshold did not display a dependence on gas saturation,
then neither would the IC threshold. The ADV findings are consistent with results
found by Kripfgans, who noted no difference in the ADV threshold in degassed or
gas saturated fluids [27]. This result goes towards rejecting the hypothesis that
heterogeneous nucleation causes the IC measured in this experimental setup.
Table 2.2: The effect of bulk fluid gas saturation, surface tension, and viscosity on the
mean (n = 5) ADV and IC thresholds. All fluids were heated to 37◦C and contained
albumin-coated, PFP droplets at a concentration of 9× 104 droplets per mL. The IC
threshold of gas-saturated water without droplets, tested under the same conditions,
was 5.6±0.2 MPa while no IC was observed for degassed water without droplets.
Gas Density Surface Viscosity Rarefactional Rarefactional
Fluid Saturation (g/mL) Tension (mPa· s) ADV Threshold IC Threshold
(mmHg O2) (mN/m) (MPa) (MPa)
Water 60 0.995 72 0.7 2.7 ± 0.2 5.7 ± 0.4
Water 170 0.995 72 0.7 2.8 ± 0.1 6.0 ± 0.3
Whole Blood 141 1.059 48 5.0 3.6 ± 0.3 7.1 ± 0.1
Glycerol (60 wt%) 60 1.146 66.9 5.2 3.3 ± 0.1 > 8.0
Glycerol (80 wt%) 60 1.199 65.7 24.7 3.8 ± 0.2 > 8.0
In the tested cases, an increase in both the ADV and IC thresholds was observed
in whole, heparanized canine blood as well as aqueous solutions of glycerol. The
relationship between the IC threshold and fluid properties such as surface tension
and viscosity has been derived by Holland and Apfel [28]. Assuming the presence
of preexisting bubbles, the IC threshold should scale directly with the bulk fluid
viscosity [28]. Our data is qualitatively consistent with this as the IC threshold
increased with increasing bulk fluid viscosity. Concerning surface tension, an
experimental study by Holland and Apfel - which measured the IC cavitation
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threshold of polystyrene spheres in water or an ethylene glycol solution - noted
a lower IC threshold in the ethylene glycol solution, which was attributed to the
reduction in surface tension [29]. For submicron-sized nuclei, the effects of decreasing
surface tension dominate, even in the case of increasing viscosity [28]. Given that
the viscosity trend and not the surface tension trend was observed, it is likely that
the IC nuclei for this experiment were not submicron in size, suggesting that the
bubbles generated by ADV were the IC nuclei.
The ADV results in whole blood are consistent with previous findings [7].
No IC was observed in the glycerol solutions with PFP droplets for the tested
pressures. Church proposes a higher IC threshold in blood due to the extra damping
associated with the higher blood viscosity [30]. It is hypothesized that bulk fluids of
higher viscosity retard the expansion of the ADV nucleus, possibly even causing a
recondensation of the vaporized nucleus at lower acoustic pressures. Therefore larger
rarefactional pressures are required to overcome this effect.
2.3.2 Droplet Parameters
Apfel patented the use of superheated immiscible droplets in medical applications
and experimentally showed that the vaporization threshold of such droplets can be
controlled using chemical ad-mixtures [6]. Droplets composed of a highly superheated
dispersed phase, relative to normal body temperature, could be vaporized with less
energy than droplets with a lower degree of superheat. The degree of superheat
is defined as the difference between the bulk fluid (or body) temperature and the
bulk boiling point of the dispersed phase. An example of the ad-mixture approach
was published by Kawabata et al., in which the ADV threshold of a PFC emulsion
was adjusted by varying the ratio of PFP to 2H,3H-perfluoropentane [12]; the latter
component has a boiling point of 53.5◦C. Table 2.1 lists the different PFC core
materials that were tested in our experiments as a function of degree of superheat.
The bulk fluid temperature was adjusted and it was assumed, due to the small size of
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the droplets, that the droplets equilibrated to the bulk fluid temperature before they
were circulated to the focus of the vaporization transducer. Due to the increased
pressure within the droplets, described by the Laplace equation, the boiling point of
the dispersed phase increases, relative to the bulk PFC boiling point, as the diameter
of the droplet decreases [31; 32]. The increase in droplet diameter from PFP to PFH
to PFO is attributed to the increase in viscosity across the homologous PFC series,
since increasing the viscosity of an emulsion phase causes an increase in particle
size [33]. Unless otherwise stated, the droplets used in the experiments had a mean
diameter as listed in Table 2.1 .
The behaviors of the ADV and IC thresholds as a function of superheat are
displayed in Fig. 2.6. All tested cases reveal an ADV threshold that is lower than
the IC threshold (p < 0.01 for both PFP and PFH droplets). For both thresholds,
an inversely proportional trend exists for negative degrees of superheat. In the
case of PFH droplets, the 95% confidence interval (CI) of the slope through the IC
data, for negative degrees of superheat is [-0.07, -0.02] with the squared correlation
coefficient (R2) equal to 0.99, thus indicating a non-zero slope. For positive degrees
of superheat, the ADV threshold remains relatively constant (95% CI of the slope of
the PFP data is [-0.03, 0.01]) as well as the IC threshold (95% CI of the slope of
the PFP data is [-0.07, 0.01]). No ADV or IC was observed for PFP, PFH, or PFO
droplets at 19◦C, 25◦C, and 63◦C below their respective bulk boiling points. An IC
threshold was observed for PFP and PFH droplets at 11◦C and 19◦C, respectively,
below the bulk boiling points, though no corresponding ADV was recorded. It is
likely that both ADV and IC occurred in these cases, but the resulting bubbles of
PFP or PFH gas either condensed or dissolved into the surrounding bulk fluid before
reaching the linear array. Therefore using the setup seen in Fig. 2.1, there are three
regions of activity for droplets with negative degrees of superheat: no ADV or IC
detected, IC without detected ADV, and both ADV and IC detected. However, if
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the experimental setup allowed for the imaging of bubbles generated at the focus
of the vaporization transducer, there are likely only two regions of activity - no
ADV or IC and both ADV and IC. The functional dependence of IC on the degree
of superheat, at least below the bulk PFC boiling point (i.e. negative degrees of
superheat), suggests that the event leading to IC is internal to the droplet. If the
ADV or IC nucleus were external to the droplet, then the probability of an IC event
external to the droplet should be relatively constant regardless of whether the PFC
is or is not superheated.
Figure 2.6: Mean (n = 5) ADV and IC thresholds, plotted with standard deviations,
for PFP and PFH droplets as a function of degree of superheat. The points denoted
with asterisks (*) are cases where IC was measured 11◦C or 19◦C below the boiling
point of PFP or PFH, respectively - though no corresponding increase in MEP was
recorded. The following conditions were used: degassed water with albumin-coated
droplets, 83 Hz PRF, and 13 cycles.
Figure 2.7 (left) displays the relationship between the ADV and IC thresholds
and the mean droplet diameter. Different droplet diameters were obtained by either
centrifuging the droplets or by allowing the droplets to grow in diameter due to
Ostwald ripening [5], as seen in Fig. 2.7 (right). The ADV threshold is inversely
41
proportional to the mean droplet diameter below 2.5 µm (95% CI of the slope is
[-1.99, -0.73], R2 = 0.86); the ADV threshold then appears to plateau for droplets
larger than 2.5 µm. This is qualitatively consistent with the diameter above which
albumin-coated PFP droplets become superheated at 37◦C (i.e. > 3.8 µm) [32; 34].
The IC threshold is statistically constant for the size range tested (95% CI of the
slope is [-0.45, 0.13]), occurring at a higher rarefactional pressure than the ADV
threshold (p < 0.001). It is important to note that the droplet distributions are
not monodispersed in size, and thus the effect of a polydisperse distribution must
be considered, such as the preferential vaporization of larger droplets for each
distribution. A similar trend, as observed in Fig. 2.7 , was obtained by plotting
the ADV threshold versus d10% or d25%, defined respectively as the droplet diameter
at which 10% or 25% of the droplets, by number, are larger than that diameter.
Extrapolating based on the inverse relationship below 2.5 µm, it becomes apparent
that submicron-sized droplets can be phase-transitioned below the corresponding IC
threshold. Particle size is known to affect the IC threshold, with smaller diameter
polystyrene spheres yielding higher IC thresholds than larger diameter polystyrene
spheres [24]. The statistically similar IC threshold for the size range of droplets
tested indicates that despite an almost sixteen fold increase in the droplet surface
area, the IC threshold does not decrease as the average droplet diameter increases.
This suggests that the IC nucleation process involved in ADV is dissimilar to the
nucleation process of IC of polystyrene spheres. It is speculated that IC nuclei are
generated from the presence of gas pockets on the surface of the spheres, due to
the hydrophobicity and surface roughness on the sphere. Considering the favorable
wettability properties of albumin and lipid shells in the bulk fluid, as well as the
high fluidity of the PFC in the dispersed phase, it may be likely that the presence of
gas pockets, compared to polystyrene spheres, is minimal.
Based on an approximate five-fold expansion of a droplet as it is vaporized into
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Figure 2.7: Left: Mean (n = 3) ADV thresholds and IC thresholds, plotted with
standard deviations, for albumin-coated PFP droplets of various mean diameters.
The points denoted with an asterisk (*) are lipid-coated droplets, whereas the other
points are albumin-coated droplets. The following conditions were used: degassed
water at 37◦C, 83 Hz PRF, and 13 cycles. Right: Increase in mean droplet diameter
over time (i.e. since day of manufacturing) for albumin-coated PFP droplets. All
droplets used in this study were manufactured on the same day and stored at 5◦C
throughout the study. Each data point, plotted with the standard deviation, is the
average of three vials.
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a gas bubble [7], a 1 µm and 10 µm droplet would yield a 5 µm and 50 µm bubble,
respectively. Using an analytical model [28], the minimum acoustic rarefactional
pressures required to produce IC in the aforementioned bubbles sizes, using a 3.5
MHz insonation frequency, are 3.77 MPa and 39.2 MPa, respectively. This is based
on a collapse temperature of 5000 K and the surface tension, viscosity, and density
of water as input parameters to the model; additionally, the heat capacity ratio of
PFP at 37◦C was determined to be 1.044 using the Universal Functional Activity
Coefficient (UNIFAC) method in Aspen Plus software (Aspen Technology Inc.,
Cambridge, MA, USA). For a micron-sized or larger bubble, the viscous and inertial
effects of the surrounding fluid cause the IC threshold to increase as the diameter
of the bubble (IC nucleus) increases. This range of computed values supports the
hypothesis that gas bubbles generated by ADV can undergo IC due the application
of US from the single-element transducer.
Figure 2.7 also displays the effect of the shell material - albumin versus lipid -
that is seemingly negligible relative to the effect of the mean diameter. For gaseous
contrast agents, lipid shells, which are on average 1 to 2 nm thick, are more stable
and inhibit diffusion due to their greater flexibility than albumin shells, which are
on average 10 to 15 nm thick and more rigid [35]. If this is the case, then the
smaller diffusion coefficients of liquid PFCs relative to gaseous PFCs coupled with
the mechanistic differences between ADV and contrast agent destruction may render
the effects of the shell negligible except for Ostwald ripening. This further indicates
that the nucleation mechanism does not occur at the shell of the droplet.
2.3.3 Acoustic Parameters
The effects of the pulse repetition frequency (PRF) on the ADV and IC thresholds
are shown in Fig. 2.8. In all cases, the ADV threshold is lower than the IC threshold
(p < 0.001). Additionally, an inverse trend is observed for both thresholds below
25 Hz while the thresholds are statistically constant above 25 Hz (95% CI of the
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slopes of ADV and IC data are [-6.3×10−5, 3.0×10−4] and [-6.7×10−4, 4.8×10−4],
respectively). The ADV and IC data above and below 25 Hz form two distinct
populations with respective p-values of < 0.03 and < 0.02. The decrease in both
thresholds, clearly seen from 10 to 100 Hz PRF, relates to the number of times a fluid
volume passing the single element transducer is exposed to an acoustic pulse. The
time needed for a new fluid volume to traverse the -6 dB beam width, based on the
average flow speed within the tube, is 40 ms (or 25 Hz). Therefore, at PRF values
less than 25 Hz each fluid volume is exposed to only a single pulse whereas above 25
Hz PRF each fluid volume is exposed to multiple pulses. The slowest and fastest
particle velocities within the tube were estimated by calculating the rate at which
the MEP increased and decreased from vaporized droplets for a specific US on-time
(i.e. a bolus of ADV generated bubbles). The velocities were calculated from the
known distance between the single-element transducer and the time delay between
the single-element transducer on-time and the passage of bubbles in the linear array
FOV; the single-element transducer on-time was also subtracted from the delay in
the decreasing MEP. The time delays were calculated based on an MEP threshold,
which was at least three-times the average MEP of the initial or final baselines (i.e.
no bubbles present). Therefore, the behavior of the MEP was similar to Fig. 2.2,
except that the MEP later decreased to the baseline value since the single-element
transducer was turned off while the linear array was still recording. The slowest and
fastest velocities were 1.2 cm·s−1 and 4.3 cm·s−1, corresponding to transit times of
67 and 19 ms, or fluid volume refresh rates of 15 and 53 Hz, respectively. Therefore,
referring back to Fig. 2.8 and considering the range of velocities in the flow tube, it
becomes evident that when a fluid volume is exposed to multiple exposures of US,
both the ADV and IC thresholds decrease relative to when a fluid volume is exposed
to only a single pulse.
The effect of pulse width on the ADV and IC thresholds is displayed in Fig.
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Figure 2.8: Mean (n = 5) ADV and IC threshold, plotted with standard deviations,
for various PRFs. The following conditions were used: degassed water at 37◦C and
13 cycles. By comparison, the rate at which a new volume of fluid crossed the -6 dB
beam width of the single-element transducer, based on the average flow velocity, was
25 Hz (middle dotted line). Therefore, each fluid volume was exposed to only a single
acoustic pulse from the single element transducer for PRFs less then 25 Hz. The left
and right dotted lines display the slowest and fastest rates, respectively, at which a
fluid volume passes the single element US beam width, based on the experimental
data.
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2.9. Two different PRFs - 10 Hz and 83 Hz - were chosen as cases where each flow
volume was exposed to a single exposure versus multiple exposures, respectively. In
both cases, for a given PRF, the ADV threshold was statistically constant (95% CI
of the slopes for 10 Hz and 83 Hz are [-0.003, 0.004] and [-0.006, 0.013], respectively)
over the range of pulse widths tested, which is consistent with results by Lo et al.
where the ADV threshold was relatively constant for microsecond pulse lengths [20].
Additionally, the IC threshold decreased as the pulse width increased, which could
imply that longer pulse widths increase the probability of interacting with a bubble
that can undergo IC, perhaps as a bubble begins to dissolve or fragment.
Figure 2.9: Mean (n = 3) ADV thresholds and IC threshold (right), plotted with
standard deviations, for various pulse widths at two different PRFs (10 Hz and 83
Hz). The following conditions were used: degassed water at 37◦C and albumin-coated
PFP droplets.
2.4 Conclusions
The elucidation of the physical mechanisms involved in ADV can allow for
the optimization of ADV in therapeutic applications such as embolotherapy and
drug delivery. Since acoustic cavitation is one possible mechanism for ADV, it is
47
important to understand the role of IC due to its bioeffects. As discussed previously,
the minimization or maximization of IC, depending on the application, may be
integral to the success of therapeutic ADV.
Table 2.3 is a summary of the presented results from Figs. 2.6 through 2.9.
Based on these results, it is possible to relate the observed trends of the ADV and
IC thresholds to physical mechanism of ADV. The possibilities include that IC helps
initiate ADV, ADV helps initiate IC (possibly by providing a bubble), or the two
events are totally uncorrelated. The correlation between ADV and IC varies for the
tested parameters. For the case of PRF, ADV and IC are highly correlated with
an R2 of 0.94, which for nine data points yields less than a 0.1% probability, the
percentage probability [36] (ProbN), that the data points are actually uncorrelated.
For droplet superheat, the R2 values are 0.74 and 0.76 for PFP and PFH droplets,
respectively; based on the number of data points, the ProbN values are less than
5.6% and 20%, respectively. Alternatively, the ADV and IC thresholds are more
uncorrelated in the cases of droplet diameter (R2 = 0.12) and pulse width (R2 = 0.39
for 10 Hz and R2 = 0.21 for 83 Hz) where the ProbN values are less than 43%, 40%,
and 50%, respectively. Given that ADV and IC are correlated for some of the tested
parameters, the next most important fact is that the ADV threshold is always less
than the IC threshold. Thus, an IC event is not necessary to cause vaporization,
though it has been shown that IC nuclei, specifically US contrast agent, external to
the droplet can lower the ADV threshold, which is beneficial in certain situations
[20]. Instead it appears that ADV occurs and (possibly) provides a bubble that
can then go through IC. The distinct nature of ADV and IC is also supported
by examining the frequency dependence of ADV and IC. It was previously shown
that the ADV threshold decreased as frequency increased [8], which is opposite of
the theoretical behavior of the IC threshold [37] and the experimental results from
Giesecke and Hynynen [22] for micron-sized PFC droplets. This may imply that the
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role of IC in ADV may change for lower frequencies since as the frequency decreases
and the IC threshold in the host medium approaches the ADV threshold, IC could
then be the dominant mechanism for triggering ADV.
Table 2.3: Summary of the effects of the various bulk fluid, droplet, and acoustic
properties on the ADV and IC thresholds. Refer to Table 2.2 and Figs. 2.6 through
2.9 for each parameter and its corresponding ADV/IC data.
Properties Parameter ADV Threshold IC Threshold
Bulk Fluid Gas saturation No effect No effect
Viscosity Direct Direct
Droplet PFC superheat Inverse (below boiling point) Inverse (below boiling point)
No effect (above boiling point) No effect (above boiling point)
Diameter Inverse (1 - 2.5 µm) No effect
No effect (2.5 - 5 µm) No effect
Shell No effect No effect
Acoustic PRF No effect (multiple US exposures) No effect (multiple US exposures)
Pulse width No effect Inverse
Knowing that ADV and IC are related, the next point of interest is to determine
where the nucleation for ADV and IC occur. Since the IC threshold remained
constant when the gas saturation of the bulk fluid was changed, as well as when the
droplet diameter increased, it is likely that the nucleus for IC is not external to the
droplet and may be the ADV bubble itself. This is supported by the IC threshold
correlation with viscosity and not surface tension, which indicated that the IC nuclei
were likely greater than one micron. However, high-speed photography would be
needed to definitively verify this. Additionally, both thresholds are dependent on
the degree of superheat of the dispersed phase, thereby suggesting that the nucleus
of ADV or IC is within the droplet. This is further supported by the fact that the
droplet shell material did not affect the ADV threshold. Interestingly, the viscosity
of the bulk fluid - which is known to affect the IC threshold - also influenced the
ADV threshold. It is possible that a viscous fluid retards the initial expansion of
the gas bubble generated by ADV, even causing recondensation of the gas nucleus
at lower rarefactional pressures due to increasing pressure within the collapsing
gas nucleus. Overall, the IC threshold occurred at a higher rarefactional pressure
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than the ADV threshold. Therefore, it is possible to operate with a given set of
experimental parameters and achieve either ADV with IC or ADV without IC. The
results suggest that the ADV nucleus is internal to the droplet and within the PFC
phase while the IC nucleus may be the bubble generated by ADV.
Additional studies will be needed to further understand the initiation mechanism
for ADV. This work can assist future in vivo studies by the selection of a droplet
formulation and acoustic parameters that can be vaporized with or without IC,
depending on the intended therapeutic application.
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CHAPTER III
Delivery of Chlorambucil using an
Acoustically-Triggered, Perfluoropentane Emulsion
3.1 Introduction
Perfluorocarbon (PFC) colloids, either microbubbles or emulsions, are being
studied in diagnostic and therapeutic applications of ultrasound (US). The use of
these colloids as delivery systems, either for therapeutic agents or genetic material,
is motivated by their spatially and temporally-selective activation via US. Recent
reviews [1–3] highlight examples of drug and gene delivery using microbubbles.
The incorporation of the drug or gene is typically accomplished using one of the
following methods: attachment (covalent or non-covalent) to the shell either directly
or using a secondary carrier, such as a liposome or nanoparticle [4; 5]; intercalation
within the shell [6; 7]; or incorporation within a fluid inside the shell. The last
technique is employed in acoustically active lipospheres (AALs) [8; 9], and is thus
amenable to the dissolution of lipophilic drugs, including chemotherapy agents
such as paclitaxel [10; 11]; alternatively, hydrophilic or lipophilic agents can be
incorporated into US activated echogenic liposomes [12]. The ability to localize the
release of a chemotherapeutic agent via US could be used to increase the local drug
concentration at the intended, target site while minimizing the overall systemic
toxicity. This could expand the therapeutic window of many chemotherapeutics that
possess a narrow distinction between efficacy and unacceptable toxicity [13].
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Though not as echogenic as microbubble-based delivery systems, unless phase-
transitioned or accumulated due to targeting, PFC liquid emulsions are also being
studied as delivery systems due to their increased circulation half-life relative to
microbubbles [14]. Additionally, compared to microbubbles, stable PFC emulsions
can be formulated with mean diameters of about 200 nm [15]. These nanoparticles
can extravasate in the microvasculature of tumors due to the presence of large
inter-endothelial gaps [16]. Formulation approaches, similar to those used for
microbubble delivery systems, have been used for PFC emulsions [17–20] due to
the hydrophobicity and lipophobicity of the dispersed, PFC phase [21]. These PFC
emulsions can be activated (i.e. phase transitioned from a liquid to a gas) either
thermally upon systemic injection [22], or via US, a mechanism termed acoustic
droplet vaporization (ADV) [23–25]. ADV is a threshold phenomenon where the
phase-transition can only take place if the acoustic amplitudes are greater than a
particular threshold value. In the case of ADV, the resulting gas bubbles have been
used in vivo to selectively reduce cerebral [26] and renal [27] perfusion.
This study focuses on the characterization and in vitro performance of an ADV-
triggered emulsion, termed a dual-phase emulsion, that contains both chlorambucil
(CHL) and PFC. CHL is a lipophilic nitrogen mustard derivative that, similar to
other alkylating agents, is predominately non-cell cycle specific. CHL has been used
clinically to treat chronic lymphatic leukemia and lymphoma as well as advanced
ovarian and breast cancers [28]. The use of CHL is limited, despite its good oral
bioavailability (Leukeran, GlaxoSmithKline, London, United Kingdom), by its toxic
side effects that include myelosuppression and neurological toxicity [29]. Therefore,
the ability to localize the effects of CHL - by encapsulation and subsequent release
using US - could be used to minimize systemic toxicity while increasing the local
concentration of CHL at the target site. Additionally, incorporation of CHL into an
emulsion has been shown to improve the pharmacokinetic profile of the drug and
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increase its therapeutic activity relative to a CHL solution [30]. The presented PFC
emulsion is micron-sized - unlike the submicron-sized, PFC droplets investigated by
other groups [15; 17–20; 22]. The ADV-triggered drug release from this emulsion
could potentially be coupled with ADV-induced occlusion [26; 27].
This study is composed of three main sections. First, the micron-sized, PFC
emulsion is prepared and characterized, with a focus on emulsion morphology and its
effect on the ADV threshold. Second, US-activated drug release from the emulsion
is studied, in terms of growth inhibition, in chambers containing Chinese hamster
ovary (CHO) cells. Third, the relationship between droplet size, ADV efficiency (i.e.
the fraction of droplets that vaporize per US exposure), and drug release is analyzed.
3.2 Materials and Methods
3.2.1 Emulsion preparation
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless
otherwise noted. Albumin droplets were prepared by modifying a previously
established protocol [24]. Briefly, 750 µL of 4 mg/mL bovine albumin in normal
saline (0.9% w/v, Hospira Inc., Lake Forest, IL, USA) was added to a 2 mL glass
vial (Shamrock Glass, Seaford, DE, USA). Chlorambucil (CHL) was dissolved in
soybean oil at a concentration of 25 mg/mL. The soybean oil and perfluoro-n-pentane
(PFP, 29◦C normal boiling point, Alfa Aesar, Ward Hill, MA, USA) were added
gravimetrically to produce a final volume fraction of 12.5% for each component. The
vial was sealed with a rubber stopper (Shamrock Glass) and metal cap (Shamrock
Glass). The vial was then shaken for 45 seconds at 4550 cycles per minute using an
amalgamator (VialMix, Lantheus Medical Imaging, Billerica, MA, USA).
The shaken vials were refrigerated (5◦C) overnight prior to use. The droplets
were diluted in normal saline that had been filtered with a syringe filter (0.22
µm, Millex GV, Millipore, Billerica, MA, USA) and sized using a Coulter counter
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(Multisizer 3, Beckman Coulter Inc., Fullerton, CA, USA) with a 50 µm aperture.
For in vitro experiments with cells, all materials used in the droplet formulation
procedure were autoclaved and all solutions were filtered using a 0.22 µm filter to
yield sterile vials of emulsion.
3.2.2 Optical characterization of the emulsions
To determine the location of the oil (i.e. drug laden phase) within each
droplet, a fluorescent dye - Vybrant R© DiI (Invitrogen, Eugene, OR, USA) -
was used as a surrogate for CHL. The utilization of a lipophilic dye to mimic
an oil-soluble compound (such as a therapeutic agent) and to confirm where
such an oil-soluble compound would reside in a microbubble or droplet has been
used extensively in microscopy or drug release studies [8; 10; 11; 31; 32]. The
resulting emulsions were diluted in normal saline and samples were aliquoted onto
a hemacytometer (Brightline, Hausser Scientific, Horsham, PA, USA). Visible and
fluorescent micrographs of the droplets were taken with a microscope (Leica DMRB,
Bannockburn, IL, USA) and camera (Spot FLEX, Diagnostic Instruments Inc.,
Sterling Heights, MI, USA) using Spot Advanced Software (Diagnostic Instruments
Inc.).
The acquired images were analyzed in MATLAB (The Mathworks Inc., Natick,
MA, USA). The pixel resolution within each image was calibrated using the
hemacytometer grid spacing. Since the emulsions contained two immiscible,
dispersed phases, the inner and outer diameters for each droplet were manually
sized. Magnification limitations restricted this manual sizing to droplets with an
outer diameter greater than or equal to 1.5 µm.
3.2.3 ADV threshold measurements
The ADV threshold was determined using identical methodologies as previously
described [33]. Briefly, diluted emulsions were exposed to acoustic pulses from
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a calibrated, 3.5 MHz single-element transducer (1.9 cm diameter, 3.81 cm focal
length, A381S, Panametrics, Olympus NDT Inc., Waltham, Ma) while in a flow tube
setup. The increase in echogenicity, recorded via B-mode US, was used to detect the
presence of bubbles generated by ADV and hence the ADV threshold.
3.2.4 Evaluation of CHL loading in emulsion
The CHL concentration in the drug-loaded emulsion was determined via high
performance liquid chromatography (HPLC) using a Hitachi 7000 series HPLC
system (Pleasanton, CA, USA). EZChrom EliteTMsoftware (Agilent Technologies,
Santa Clara, CA, USA) was used to control the system as well as acquire and process
data. The mobile phase, filtered through a 0.22 µm filter (Durapore GS, Millipore),
consisted of methanol (CHROMASOLV Plus for HPLC) and 0.1% (w/v) ammonium
acetate (65:35 (v/v)) and was pumped at 1 mL/min through a Luna R© column (C5,
150 x 4.6 mm, 5 µm, Phenomenex, Torrance, CA, USA). Samples were manually
injected using a 20 µL injector loop. The column was kept at ambient temperature
and samples were analyzed at a wavelength of 254 nm. The CHL peak eluted at
approximately 4.1 minutes.
CHL standards were prepared, via serial dilution, by dissolving CHL in a solution
of methanol and 0.1% (w/v) ammonium acetate (80:20 (v/v)). The HPLC method
was validated for linearity in the range of 1 to 500 µg/mL (R2 > 0.999) using the
CHL peak area. Triplicate injections of each standard yielded peak area variabilities
of less than 3% relative standard deviation. The ability to extract CHL from the
soybean oil was validated by adding CHL solubilized in soybean oil to 2 mL glass
vials containing 1 mL of extraction solvent - methanol and 0.1% (w/v) ammonium
acetate (80:20 (v/v)). The vial was capped, sealed, and then shaken for 45 seconds
at 4550 cycles per minute using an amalgamator in order to facilitate the extraction
of CHL. The standard was then centrifuged at 3000 rpm for 10 minutes in order
to separate the oil from the solvent. The solvent phase was then injected onto the
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HPLC. It was confirmed that complete extraction of the CHL from the oil was
achieved in this sample processing and that any solubilized soybean oil did not
chromatographically interfere with the CHL peak.
Emulsion samples were processed similarly to the CHL-laden soybean oil samples
by adding an aliquot of emulsion to methanol. The emulsion was broken by shaking
the sample, which was evident by the presence of precipitated albumin. The samples
were centrifuged and the solvent phase was injected onto the HPLC. It was validated
that this sample processing yielded complete extraction of CHL from the emulsion.
Also, it was confirmed that the presence of any solubilized albumin within the
solvent did not chromatographically interfere with the CHL peak.
3.2.5 Cytotoxicity of CHL in solution
Chinese hamster ovary (CHO) cells (American Type Culture Collection,
Manassas, VA, USA) were cultured in RPMI 1640 growth media (Invitrogen)
supplemented with 10% (v/v) defined fetal bovine serum (Hyclone, Logan, UT,
USA), 100 U/mL penicillin, and 100 µg/mL streptomycin (Invitrogen). The cells
were grown in a humidified 5% carbon dioxide environment at 37◦C. The cells
were plated at approximately 2.0×104 cells/mL, determined via Coulter counter, in
6-well microtiter plates (Fisher Scientific, Pittsburgh, PA, USA) 24 hours prior to
treatment. A CHL solution was prepared by dissolving CHL in dimethyl sulfoxide
(DMSO, Sigma-Aldrich). The cells were then incubated with varying concentrations
of CHL solution for either 15 or 60 minutes. The concentration of DMSO within
each well did not exceed 1% (v/v) in any experimental group, which consisted of 6
wells per CHL concentration as well as a control group (without DMSO or CHL) and
a group treated with DMSO alone. Following the incubation period, the medium
from each well was removed and the cells were washed in triplicate with warmed
(37◦C) Dulbecco’s phosphate buffered saline (DPBS, with calcium chloride and
magnesium chloride, Invitrogen). Fresh medium was added to each well and the cells
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were grown for an additional 48 hours post treatment. After 48 hours, the control
cells had reached approximately 80-90% confluence, which was visibly estimated
using an inverted microscope (Leica DMIL). The cells were then harvested using
typsin-EDTA (Invitrogen), centrifuged at 1200 rpm for 3 minutes, resuspended in
new medium, and counted using a Coulter counter with a 100 µm aperture. Particles
larger than 10 µm were counted as intact cells and used for subsequent calculations
[34–36].
The percent growth inhibition (GI) for each experimental group was determined
as seen in Eq. 3.1, where Ncontrol,to is the initial number of cells seeded in the
control group, Nexp,to is the initial number of cells seeded in the experimental group,
Ncontrol,tf is the final number of cells in the control group, and Nexp,tf is the final
number of cells in the experimental group.





The GI data, as a function of CHL concentration in DMSO, was fit using a sigmoidal
curve as seen in Eq. 3.2 where m1 is the maximum y-value, m2 is the minimum
y-value, m3 is the x-value at the midpoint of y, and m4 is the slope at the y-midpoint.







3.2.6 Ultrasound triggering of CHL-loaded emulsion
OptiCellTM(Thermo Fisher Scientific, Rochester, NY, USA) chambers were
coated with 20 µg/cm2 collagen (type I, BD Biosciences, Bedford, MA, USA)
24 hours prior to plating approximately 4.0×104 cells/mL CHO cells within the
chambers. The cells, seeded 24 hours prior to treatment, were grown using the
same conditions as previously described for the 6-well plate experiments. Figure
3.1 displays the experimental setup and exposure conditions. For experimental
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groups treated with droplets, the emulsion was diluted with DPBS and introduced
into the OptiCellTM, yielding a concentration of 7.0×107 droplets/mL within the
chamber. The chamber was gently and repeatedly inverted to homogenously mix
the droplets, then inverted to allow the droplets to settle onto the bottom window;
the chamber was then placed into the OptiCellTMholder which was located within
a tank (40 × 60 × 27 cm) that contained degassed, deionized water heated to
37◦C (Ex 7, ThermoNESLAB, Newington, NH, USA). The surface of the tank
water, located 5 cm above the OptiCellTM, was covered with air-filled plastic balls
(Cole-Parmer Inc., Vernon Hills, IL, USA) to minimize regassing and heat loss as
well as to reduce the planar reflection of the US at the air/water surface. A linear
array (10L probe, Logiq 9, GE Healthcare, Milwaukee, WI, USA) operating at the
following conditions - 6.3 MHz, contrast mode, single focus at 2.5 cm, 1.57 MPa
peak rarefactional focal pressure, 0.8 µs pulse duration per scan line, 12 kHz scan
line pulse repetition frequency, 10 Hz frame rate - was positioned below the chamber
such that the 2.5 cm focus was at the bottom window of the chamber. The array was
rastered in a minimally-overlapping manner, via a computer-controlled positioning
system, at 2 mm/s across the chamber surface in order to vaporize the emulsion.
Only two rasters of the linear array were required to insonify the entire chamber
(approximately 75 seconds to scan the entire chamber). Following the exposure,
the chamber was removed from the tank, inverted so that the cells were once again
on the bottom window, and incubated for 60 minutes. During the incubation, any
droplets that did not vaporize remained in contact with the cells; bubbles, and hence
PFP gas, generated due to ADV were not in contact with the cells due to their
buoyancy and size. The chamber was then washed using similar methods as used
for the 6-well plate experiments and the cells were grown for another 48 hours post
washing. The cells were counted as previously described and the GI was calculated
for all experimental groups listed in Table 3.1. Due to the fluid movement into and
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out of the OptiCellTMduring washing, a relatively large shear force was exerted on
the cells adjacent to the OptiCellTMinjection port, resulting in their deplating. The
GI for each chamber was normalized by the deplated area to account for this loss.
All control groups received the same handling during the exposure and washing
processes. The same CHL concentration was used for groups receiving CHL in
DMSO or emulsified CHL. Analysis of variance (ANOVA) was used to establish the
significance between the different experimental groups. The Tukey-Kramer method














Wash + replace 
medium
Figure 3.1: Left: Experimental setup used to perform ADV experiments with
OptiCellsTM. Right: Exposure conditions utilized during experiments. The emulsion
was added to the chamber containing adherent CHO cells and subsequently exposed
to US to cause ADV of the introduced droplets.
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Table 3.1: Groups used in the OptiCellTMexperiments. For each group, the positive
(+) and negative (−) symbols indicate the presence or absence, respectively, of each
parameter. In the case of group 5 or 8, the CHL is present within the dispersed phase
of the emulsion.
Group Droplets CHL US
1 − − −
2 + − −
3 − + −
4 − − +
5 + + −
6 + − +
7 − + +
8 + + +
3.2.7 ADV efficiency
The ADV efficiency in the OptiCellTM, using the experimental setup and acoustic
parameters from the previous section, was determined using chambers without cells.
The emulsion was introduced into the chamber, exposed to US, and the droplets
remaining post-exposure were counted with the Coulter counter. The droplet
sample was briefly over-pressurized in a syringe and then diluted prior to counting,
thereby decreasing the likelihood that bubbles were still present in solution. The
ADV efficiency was defined as the ratio of the droplet concentration remaining in
the chamber post US exposure to the initial droplet concentration (i.e. before US
exposure). The experiment was repeated using 1, 2, and 5 passes of the US array
across the chamber surface.
3.3 Results
3.3.1 Emulsion characterization
Figure 3.2 displays the visible and fluorescent images of the droplets, where two
distinct phases are clearly seen within the droplets. The dye is contained within
the oil phase due to the lipophilicity of the dye and the lipophobicity, and also
hydrophobicity, of the PFP phase [21]. The oil phase surrounds the PFP core due
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to the relative hydrophobicites of the two phases; fluorocarbons are significantly
more hydrophobic than hydrocarbons [21]. A similarly structured emulsion, with a
fluorocarbon surrounded by oil, was observed when silicone was emulsified with a
perfluoropolyether and water [32].
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Figure 3.2: A visible image (left) and its corresponding fluorescent image (right) of
the dual-phase emulsion containing PFP and soybean oil stained with a fluorescent
dye. The spacing between the two horizontal lines on the hemacytometer is 200 µm.
A 20 µm scale is included in each image. Although large droplets appear in this
figure, droplets larger than 10 µm in diameter account for only 4.9% (by number) of
total droplets. Refer to Fig. 3.4 for a size distribution, obtained via Coulter counter,
for the emulsion.
Based on the micrographs, Fig. 3.3 displays the ratio of the inner droplet
diameter (PFP) to the outer droplet diameter (PFP plus soybean oil) for the
emulsion. Microscopy magnification limitations prevented the optical sizing of
droplets with outer diameters smaller than 1.5 µm. Even though these smaller
droplets could not be sized, it is evident that as the outer droplet diameter increases,
the ratio of the inner to outer diameter also increases. Therefore, larger droplets
tend to have a larger volume percentage of PFP relative to smaller droplets and
a tighter distribution of the ratio. It also appears that there is a cutoff for each
droplet diameter that limits how small the ratio may be for a given size. The ratio
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distribution has a slight positive skew with a mean ratio of 0.45. The actual outer
diameter size distribution, as obtained by the Coulter counter, is displayed in Fig.
3.4.
Figure 3.3: Left: For n = 338 droplets, the ratio of the inner to outer droplet diameter
is plotted as a function of the outer droplet diameter. The raw data is plotted using
open, gray circles and the averaged, binned (1 µm) data is presented as closed, black
circles. Right: A histogram of the raw data.
Characterizing the ratio of the inner and outer droplet diameters may enable
a clearer interpretation of the ADV threshold for the dual-phase emulsion, which
is seen in Fig. 3.5. Previous findings using PFP droplets [33] demonstrated that
the ADV threshold was inversely proportional to the mean droplet diameter below
2.5 µm and relatively constant for mean droplet diameters larger than 2.5 µm; the
shell material, either albumin or lipid, had a negligible effect on the ADV threshold.
The ADV thresholds for the dual-phase droplets as a function of their outer droplet
diameter (solid squares) is plotted along with the ADV threshold for single-phase
droplets (x’s) from previous work [33]. Using the results from Fig. 3.3, the mean
inner diameter of the dual-phase droplets can be estimated based on the mean outer
diameter so that the plotted diameters are the PFP core diameters (open squares).
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Figure 3.4: The emulsion size distribution, obtained using a Coulter counter, plotted
as the number percent of total droplets. The 50 µm aperture enables the sizing of
particles whose diameters are between 1 and 30 µm. The mean droplet diameter is
3.06 ± 0.21 µm with 4.9% (by number) of the droplets larger than 10 µm in diameter.
The CHL loading in the droplets is 3.12 ± 0.01 mg/mL emulsion.
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Figure 3.5: A comparison of the mean (n = 3) ADV thresholds, plotted with stan-
dard deviations, for single-phase and dual-phase droplets as a function of average
droplet diameter. The single-phase ADV thresholds are taken from a previous study
[33]. The dual-phase droplets with a mean diameter of 6.96 µm were obtained by
centrifuging the emulsion. The data labeled ‘dual-phase (shifted)’ has been corrected
for the estimated mean PFP core diameter, using Fig. 3.3. The horizontal error bars
were obtained based on the standard deviation in Fig. 3.3 (right). The following
experimental conditions were used: degassed water at 37◦C, 3.5 MHz single element
transducer, 83 Hz pulse repetition frequency, and 13 cycles.
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3.3.2 CHL cytotoxicity on CHO cells
Figure 3.6 displays the cytotoxicity of CHL initially dissolved in DMSO on
CHO cells for 15 and 60-minute exposures. The group treated with DMSO alone
yielded a GI that was not statistically different (p > 0.01) than the control group
(without DMSO or CHL). Based on the sigmoidal curve fits (R2 > 0.99 in both
cases), the CHL concentration required to produce 50% GI was 167 µM and 57
µM, respectively, for 15 and 60-minute exposures. By comparison, the IC99 - the
concentration required to kill 99% of cultured cells - was 20 µM and 60 µM for 1-hour
exposures of CHL with murine P388 tumor cells at a pH of 7.2 and 7.8, respectively
[37]. Similarly, CHO and human SKOV3 adenocarcinoma cells incubated with CHL
for 48 hours yielded IC50 values, similarly defined as IC99, of 40 µM [38] and 8.5 µM
[30], respectively. As is evident, cancer cells are more susceptible to CHL, which
displays a log-linear dose response effect, than normal (ex. CHO) cells since the
former are more likely to be in cell cycle at any given time [39]. Additionally, cancer
cells are slower than normal cells in repairing cellular damage induced by exposure
to cytotoxic agents [13].
Figure 3.6 also displays the linear correlation (R2 > 0.94) between the mean CHO
cell diameter 48 hours post-incubation and the GI for the CHL in DMSO data. The
increase in mean cell diameter can be used as an indicator of CHL exposure. Cell
volume, and hence diameter, is known to increase in response to exposure to a variety
of chemotherapeutic agents, including CHL [40; 41]. Though not fully understood,
the increase in cell volume is likely due to the continued protein synthesis by the
cell despite the disruption in DNA synthesis and function. If the GI is due to CHL
and additional factors, as will be discussed below, the change in mean cell diameter
should only be used as a qualitative indicator of whether CHL was or was not a
contributor to GI.
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Figure 3.6: Left: Cytotoxicity of CHL initially dissolved in DMSO on CHO cells for
15 and 60-minute exposures. Right: The mean CHO cell diameter as a function of
the GI. For both the left and right plots, each data point is the average of six wells,
from three independent experiments. Additionally, error bars are standard deviations
of the means.
3.3.3 Ultrasound triggering of the CHL-loaded emulsion
Figure 3.7 displays the GI for the eight experimental groups 48 hours post
treatment and Table 3.2 lists the results of Tukey’s test for the groups. As per the
definition of GI (Eq. 3.1), the control group (group 1) has a mean GI of zero. The
application of US (group 4) yielded a GI that was not statistically different from the
control group.
The blank emulsion alone (group 2) and the combination of US with the blank
emulsion (group 6) yielded 18.6 ± 3.4% GI and 22.6 ± 2.4% GI, respectively.
Inverting group 2 during the 60-minute incubation period (i.e. droplets were not in
direct contact with the cells - see Fig. 3.1) resulted in a 17.0 ± 7.6% GI, indicating
that merely the presence of sham droplets within the chamber caused GI. It was
found that the GI experienced by group 2 was a result of increased detachment of the
CHO cells during the washing of the chamber when droplets were introduced. Cell








































































Figure 3.7: Mean (n = 5) percent GI and standard deviation for each of the eight
experimental groups. The presence (+) or absence (−) of each parameter - droplets,
CHL, and US - is indicated above each group number. The same exposure procedure,
acoustic parameters, droplet concentration, and CHL concentration (100 µM whether
in DMSO or emulsified) was used for all groups.
Table 3.2: Results of Tukey’s test on percent GI (upper right triangle) and mean
diameter (lower left triangle) data. An ‘x’ indicates groups that are not statistically
different at a 0.01 or 0.05 level. Statistically significant differences at a 0.01 or 0.05
level are indicated by ‘0.01’ and ‘0.05’, respectively.
Group 1 2 3 4 5 6 7 8
1 0.01 0.01 x 0.01 0.01 0.01 0.01
2 x 0.01 0.01 0.01 x 0.01 0.01
3 0.01 0.01 0.01 0.01 0.01 x x
4 x x 0.01 0.01 0.01 0.01 0.01
5 0.01 0.01 0.01 0.01 0.01 0.01 0.01
6 x x 0.01 x 0.01 0.01 0.01
7 0.01 0.01 0.05 0.01 0.05 0.01 x
8 0.01 0.01 0.01 0.01 x 0.01 x
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chamber growth surfaces, unlike the rigid nature of conventional microtiter plates.
Therefore, OptiCellsTMcan be coated with fibronectin or collagen, as was done in
this manuscript, to minimize cell detachment. Despite coating the chambers with
collagen, cell detachment was still appreciable during the vigorous washing step.
The washing step was critical in ensuring that the cells were not incubated with
drug-carrying emulsion after the 1-hour treatment. This detachment was confirmed,
via microscopy and using the Coulter counter, by adding the blank emulsion to
the chamber and then immediately washing the chamber. The droplets became
attached to the cells following their introduction into the chamber, possibly due to
an electrostatic interaction. During the washing of the chamber, the adherence of
the droplets to the cells coupled with the vigorous movement of droplets during
the procedure caused this GI. Different emulsion shells or different cell types could
influence the amount of droplet attachment, and therefore the amount of cells that
are deplated. All of these effects lie outside of the intended demonstration of drug
release by ADV and were considered as correction factors in the final examination of
drug release described below. Additionally, it is not known whether these deplated
cells would have been viable had they not been deplated.
Groups 2 and 6 were not statistically different (p > 0.05), indicating the ADV
process (group 6) did not cause any additional GI when compared to the droplets
alone (group 2). The GI experienced by group 6 may include two potentially
offsetting phenomena: 1) the reduction in the number of droplets due to ADV, and
thus the decrease in cell detachment due to a decrease in droplet shearing; 2) GI
induced by the ADV process itself. This second phenomena is clearly obtained when
the chamber is not inverted prior to US exposure (see Fig. 3.1). When the droplets
are resting on the cells and they are vaporized, there is a 74.9 ± 8.5% GI. However
again, the viability of these detached cells is unknown since they are removed from
the OptiCellTMduring the washing.
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The groups treated with CHL in DMSO (group 3) and CHL in DMSO with US
(group 7) yielded GI values of 83.3 ± 2.5% and 77.7 ± 1.5%, respectively, which is
similar to the results obtained at the same concentration in Fig. 3.6. Additionally,
groups 3 and 7 are not statistically different (p > 0.05), which is expected assuming
a lack of appropriately-sized cavitation nuclei within the medium lacking droplets.
The groups treated with emulsified CHL (group 5) and emulsified CHL with US
(group 8) experienced 46.7 ± 7.6% and 84.3 ± 3.8% GI, respectively. Groups 5 and
8 are statistically different (see Table 3.2) indicating that the application of US did
cause an increase in CHL release from the emulsion. Since group 5 is statistically
different from both groups 3 and 7, and group 8 is not statistically different from
groups 3 and 7, it can be surmised that the retention of CHL within the emulsion
reduces its cytotoxicity until US is applied. Upon insonation, the cytotoxicity of
emulsified CHL is equivalent to non-emulsified CHL (i.e. CHL in DMSO, group 3).
It should be noted that a portion of the GI for groups 5 and 8 was due not only
to CHL release (via leakage or US), but also the droplet-cell adhesion described
above for groups 2 and 6. To determine the percent GI caused by CHL release, the
effects of the droplets and ADV must be estimated. One option is to subtract the
approximate 20% GI experienced by groups 2 and 6 from groups 5 and 8 in Fig. 3.7.
Alternatively, groups 5 and 8 could be scaled by a fraction of 20% GI, considering
that some of the cells exposed to CHL will also be removed during the washing of
the chamber.
Figure 3.8 displays the mean cell diameter for the eight experimental groups. As
indicated in Fig. 3.6, the average cell diameter can be used to assess whether CHL
exposure contributed to GI. The level of CHL exposure can only be estimated from
Fig. 3.1 if no other factors contributed to the GI. Groups that were not exposed to
CHL - 1, 2, 4, and 6 - possessed mean diameters that were not statistically different
(Table 3.2), when comparing any of the two groups. Groups 3 and 8 are statistically
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different, suggesting that the GI observed in group 8 is not solely due to the presence
of CHL but from other factors such as droplets or ADV. Additionally, groups 3 and
7 are statistically different, though only at a 0.05 level. Group 5 displayed a smaller
average cell diameter than group 8, but the groups are not statistically different
(p > 0.05), implying that the dominant cause of GI in group 8 is caused by CHL
exposure. Overall, the GI obtained via cell counts is a more robust metric, when
compared to using the mean cell diameter, though the latter metric can be used to

























































































Figure 3.8: Mean (n = 5) cell diameter and standard deviation for each of the eight
experimental groups. The presence (+) or absence (−) of each parameter - droplets,
CHL, and US - is indicated above each group number. The same exposure procedure,
acoustic parameters, droplet concentration, and CHL concentration (100 µM whether
in DMSO or emulsified) was used for all groups.
3.3.4 ADV efficiency
Figure 3.9 displays the ADV efficiency - the fraction of droplets that vaporize
- as a function of droplet diameter. The ADV efficiency was measured with a
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Coulter counter using the same setup described in Fig. 3.1. A sigmoidal relationship
exists between the fraction of droplets vaporized and the droplet diameter, with the
ADV efficiency relatively constant above 12 µm. The direct correlation between
droplet diameter and ADV efficiency, at least between 2 and 12 µm, is qualitatively
consistent with a probability of ADV stemming from the droplet distribution (i.e.
larger droplets have larger PFP cores (Fig. 3.3) that are more likely to possess nuclei
that could facilitate ADV).
Figure 3.9: The number and volume weighted distributions for the dual-phase droplets
are plotted along with the mean (n = 3) fraction of droplets vaporized, as a function
of droplet size, for different number of exposure passes by the US array. The standard
deviation is plotted for the single pass case, with similarly sized standard deviations
obtained for the 2 and 5 pass cases. The small decrease in efficiency between 1 and
2 µm is due to the subtraction errors between the treated (with US) and untreated
(without US) cases.
Repeated passes of the US array across the chamber cause further ADV of
remaining droplets, though the incremental difference in efficiency is larger going
from 0 to 1 passes (where it was shown that no recordable droplet vaporization
occurred by merely adding the droplets in the chamber and subsequently withdrawing
them) than from 1 to 2 passes. This supports the possibility that for each pass of
the US array, a constant fraction of the remaining droplets undergo ADV.
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3.4 Discussion
This study focuses on the development of a micron-sized, drug delivery vehicle -
containing a superheated PFC phase - which releases the drug payload upon ADV
of the PFC. Other groups formulating drug-carrying PFC emulsions have focused
on submicron sized droplets [17–20; 22]. The use of micron-sized droplets that are
transpulmonary enables the coupling of ADV-induced drug delivery and localized
occlusion. Localized occlusion results from relatively large microbubbles blocking
perfusion at the capillary level. This selective generation of transient, vascular
occlusion has been previously demonstrated in vivo [26; 27]. ADV-induced occlusion
can complement ADV-induced drug delivery in two ways. First, the ischemic
conditions created could increase the residence time of therapeutic material at the
intended site, resulting in greater diffusion into the target tissue. A simple example
of this phenomenon is obtained by comparing the 50% GI concentration for CHO
cells when incubated with CHL for either 15 minutes (167 µM) or 60 minutes (57
µM). Second, the ischemic conditions can generate hypoxia that could be used to
activate bioreductive prodrugs [42] that may be encapsulated within the emulsion.
Thus, the proof-of-concept studies presented here serve as a foundation in developing
future therapies that incorporate ADV.
The emulsion discussed in this work was prepared using a single emulsification
step with only an aqueous-soluble surfactant, similar to other drug-carrying PFC
emulsions [17; 18] and contrast agents [7; 10; 11]. In contrast, double emulsions
are typically prepared in two stages with two types of surfactants, where the
innermost droplets are first emulsified followed by their subsequent emulsification
in a secondary fluid [43]. The presence of natural emulsifiers within soybean oil,
including phospholipids [44] may help stabilize the PFP core.
The effect on the ADV threshold of encapsulating the PFP core within a layer of
oil is currently unknown, though from Fig. 3.5 it does not appear to be as significant
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for smaller droplets as larger droplets. In the case of AALs, the presence of an oil
layer causes the pulse length required for contrast agent destruction to increase at
least five-fold relative to contrast agent without an oil shell [9]. The thickness of the
oil-lipid layer in AALs is 500 to 1000 nm and 300 to 700 nm for AALs containing
triacetin and soybean oil, respectively [9]. By comparison, the mean oil-albumin
layer thickness for the dual-phase droplets described in this study, measured using
optical microscopy, is 1390 ± 720 nm. It is possible that the oil layer could inhibit
or dampen the expansion of any gas nuclei generated within the PFP core during
the ADV process, possibly even causing a recondensation of the PFP at lower
rarefactional pressures. This is similar to results where the ADV threshold of PFP
droplets increased as the viscosity of the bulk fluid containing the droplets increased
[33].
Concerning the GI observed for group 2, PFC emulsions are known to cause
cellular growth inhibition, but only in phagocytic cell lines [45; 46]. While this GI
was well explained by droplet-cell adhesion and subsequent detachment from the
OptiCellTMduring washing, it was also hypothesized that the GI experienced by
group 2 might be attributable to the fact that PFC emulsions can modulate the
oxygen content of media due to their high gas dissolving capabilities [21; 47]. Based
on the amount of PFP injected into each chamber and the solubility of oxygen in
PFP - 80% (v/v) [48] - the maximum change in the oxygen concentration within
the chamber, assuming that the PFP did not initially contain any oxygen, is 10%
by weight. Hypoxic conditions can decrease the growth rate of CHO cells, but only
when the cells are exposed to an oxygen concentration less than 3.5%, relative to
the atmospheric oxygen concentration, for prolonged periods (i.e. > 10 hrs) [49]. By
comparison, after injecting the emulsion into the OptiCellTM, the measured change
in dissolved oxygen concentration was negligible (i.e. less than 1%) over one hour.
This is likely due to the gas permeable nature of the OptiCellTMwindows and that
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the PFP was partially saturated with oxygen prior to injection due to atmospheric
contact.
The cellular bioeffects of ADV are currently unknown, though some insights can
be obtained from the presented studies. The cell detachment due to the ADV process
may be a result of droplet displacement prior to vaporization, where velocities up to
20 m/s have been recorded [50]. Additionally, the rapid consumption of the liquid
PFP and expansion of the resulting bubble during the ADV process [51], combined
with bioeffects stemming from cavitation [52], could cause cell detachment. It is
unknown whether ADV could cause cell detachment in vivo or if the vaporization
process could cause increased cell or vascular permeability, similar to results observed
with microbubble cavitation [1; 2].
Since the intended mechanism of drug release from the dual-phase emulsion is
US, the ADV efficiency is directly related to the amount of oil, and hence CHL,
that could be potentially available for cellular exposure. As seen in Fig. 3.5, an
inverse trend exists between the ADV threshold and the droplet diameter. Though
this trend is confounded by the use of polydisperse droplets, it is hypothesized that
droplets with a lower ADV threshold will also display a higher ADV efficiency for a
given acoustic exposure. Additionally, it is possible that the ADV efficiency trend
observed in Fig. 3.9 can be attributed to the distribution of rarefactional pressures
within the focal volume of the US array as well as the duration in which droplets of
a given diameter are exposed to rarefactional pressures greater than their respective
ADV thresholds. Assuming an infinite US exposure duration at a given acoustic
pressure, while neglecting the dissolution of the droplets, the ADV efficiency should
either be zero (for small droplets whose diameters render high ADV thresholds) or
one. The step function dependence of the ADV efficiency, with respect to droplet
diameter, is supported by computing the slopes of the ADV efficiency data between
2 to 12 µm. The slopes - which increase as the number of exposure passes increases
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- are 0.07, 0.09, and 0.10 µm−1 for 1, 2, and 5 passes, respectively.
The inverse relationship between ADV threshold and droplet diameter is similar
to the relationship between the thermal vaporization temperature of PFP droplets
and droplet diameter. Using the Laplace pressure and Antoine equations, the
diameter above which PFP droplets will undergo thermal vaporization at 37◦C is 6.4
µm and 4.0 µm for surface tensions of 50 mN/m and 30 mN/m, respectively [20]; shell
effects beyond surface tension reduction are ignored in these estimates. Therefore,
the distinct ADV thresholds and defined ADV efficiencies of the emulsions, coupled
with the observation that PFP emulsions are thermally stable up to 60◦C [24],
indicate these emulsions are relatively free of nuclei that enable the emulsion to
stably exist in a superheated state.
Table 3.3 lists the fraction of total droplets vaporized in terms of both number
and volume weighted distributions. The droplets in the 1 to 6 µm range are
transpulmonary, and thus amenable to intravenous administration, whereas the
droplets in the 6 to 30 µm range are amenable to intra-arterial administration. The
number and volume-weighted fractions (without volume correction) were estimated
by using the respective distributions and ADV efficiency in Fig. 3.9. The volume
corrected fractions were estimated by correlating the ratio of the inner to outer
diameter to the outer droplet diameter (Fig. 3.3). This correction was then applied
to determine the volume of oil, and thus CHL, released upon ADV. The correction
has a more significant impact on the larger droplets that, as seen in Fig. 3.3, have
a larger PFP core. Thus, for a single pass of the US array - which was used in the
cell experiments - approximately 50% of the oil is released upon ADV. Assuming an
equal distribution of CHL within the oil, the actual concentration of CHL released
via ADV in the chamber is 50 µM, which causes a 51% GI (based on Fig. 3.6).
In Fig. 3.7, group 8 displayed an 84.3% GI, which when the GI caused by the
emulsion alone (groups 2 and 6) is subtracted, the percent GI from released CHL is
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approximately 64.3%. This is qualitatively consistent with the percent GI predicted
by the ADV efficiency.
Table 3.3: The fraction of total droplets vaporized, expressed in terms of number
and volume fraction. The data without volume correction is the fraction of droplets
vaporized, based on Fig. 3.9. The volume corrected data uses the relationship between
the inner and outer droplet diameters (Fig. 3.3) to estimate the fraction of oil released.
Diameter Counts Volume Number of Passes
Range corrected 1 2 5
Number No 0.08 0.11 0.10
1 - 6 µm Volume No 0.01 0.02 0.02
Volume Yes 0.01 0.02 0.02
Number No 0.06 0.08 0.08
6 - 30 µm Volume No 0.72 0.85 0.83
Volume Yes 0.49 0.58 0.57
3.5 Conclusions
In summary, a stable, superheated, micron-sized emulsion has been developed
that carries a lipophilic, therapeutic agent. The emulsion is triggered via US
to produce gas bubbles and enhance the release of the encapsulated agent, as
demonstrated with cultured cells. Current efforts are focused on increasing the drug
loading of the dual-phase emulsions, minimizing the effect of non-US related drug
release, and controlling the size distribution of the emulsions.
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CHAPTER IV




Particles that release a therapeutic payload upon interaction with an internal
stimulus, such as pH or hypoxia, or the application of an externally-applied
stimulus, such as heat or ultrasound (US), are being studied in an effort to
localize drug delivery to target areas [1–5]. The control of localized delivery is
especially important for drugs that possess narrow therapeutic windows, thereby
minimizing systemic side-effects. US-triggered drug delivery is unique since US
affords diagnostic and therapeutic capabilities, spatial and temporal control of
delivery, and the ability to focus onto deeply located tissues. The interaction of US
with payload-containing particles can generate acoustic cavitation, heating, radiation
forces, and sonoporation. The last effect, the transient increase in cell membrane
permeability, can greatly enhance the uptake of drugs, genes, and peptides contained
within US-activated particles [6–9]. These particle-US interactions can also produce
therapeutic effects to be utilized in diverse applications such as thrombolysis [10] or
in the reversible disruption of the blood-brain barrier [11].
Colloidal particles utilized in US-mediated drug release are typically shell-
stabilized microbubbles or droplets containing, respectively, perfluorocarbon (PFC)
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gases or liquids. The former colloids evolved from clinically-utilized US contrast
agents, which are micron-sized gas bubbles that increase the echogenicity in perfused
tissue upon intravenous administration. Due to their size, the microbubbles are
transpulmonary and resonant at frequencies utilized in clinical imaging systems [12].
Therapeutic agents are typically incorporated into the microbubbles using one of the
following methods: attachment to or intercalation within the shell; complexation of
secondary carriers to the microbubble shell; or incorporation within a fluid inside
the shell [13; 14].
As highlighted in a recent review [15], PFC emulsions have also been studied as
US contrast agents and drug delivery systems due to their increased stability, longer
circulation times, and ability to extravasate if formulated as nanoparticles. Due to
the hydrophobicity and lipophobicity of the dispersed PFC phase [16], therapeutic
agents are typically loaded into the emulsion using similar techniques as those
mentioned for microbubble delivery systems. One commonly utilized method is the
use of an oil-phase, containing the therapeutic agent, co-emulsified with the PFC
phase during formulation [17–20]. PFC emulsions, with or without a therapeutic
payload, can be vaporized into gas bubbles using US, a mechanism termed acoustic
droplet vaporization (ADV) [21–25]. ADV is a phenomenon whereby vaporization
occurs only if the emulsion is exposed to acoustic amplitudes greater than a threshold
value. PFCs used in emulsions suitable for ADV applications typically possess
bulk boiling points that are lower than normal body temperature (37◦C), such as
perfluoropentane (29◦C boiling point). Upon injection in vivo, the emulsions do
not spontaneously vaporize due to the increased internal (i.e. Laplace) pressure,
and hence boiling point elevation, of the PFC when formulated as droplets [25].
Low boiling point PFCs, such as perfluoropentane, also enable the use of lower
acoustic amplitudes to generate ADV [17] and the production of stable gas bubbles
in vivo [26–28]. The ADV of PFC emulsions containing a lipophilic, therapeutic
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payload can be used to facilitate the delivery and release of the therapeutic agent,
as demonstrated with in vitro [17–20] and in vivo [25] studies.
The ADV of micron-sized PFC emulsions, administered intravenously or
intraarterially, has also been used to generate localized, vascular occlusion in
vivo [26–28]. The temporal duration of an ADV-generated occlusion is transient,
especially for gas emboli generated from intravenously administered emulsions [28].
Therefore, the ability to extend this duration may be therapeutically beneficial
for surgical applications that require longer occlusion times such as radiofrequency
ablation [29] and high intensity focused US thermal therapy [30]. ADV-generated
occlusion could also be potentially used to treat hemorrhaging associated with
vascular damage or other internal bleeding, which are currently treated using
transcatheter embolization [31; 32]. One option is the simultaneous formation of a
chemically-generated embolus and gas embolus within the feeder artery of the target
tissue, thereby prolonging the duration of ADV-generated embolization. Chemical
embolic agents - such as N-butyl cyanoacrylate, ethylene vinyl alcohol copolymer,
and Eudragit E-100 (used in the treatment of arteriovenous malformations [33–35])
or thrombin (used in the treatment of pseudoaneurysms [36; 37]) - are typically
administered via the use of a catheter. Therefore, the encapsulation of a chemical
embolic agent within a PFC emulsion could provide a minimally-invasive means of
producing a localized, sustained embolization via ADV with millimeter precision and
without the use of ionizing fluoroscopy.
The aim of this study was to develop a PFC emulsion containing a water-soluble,
chemical embolic agent - thereby expanding the range of therapeutic agents delivered
via ADV beyond oil-soluble compounds. The micron-sized, PFC emulsions were
formulated as double emulsions with the following structure: water-in-PFC-in-water
(W1/PFC/W2). These double emulsions can serve as a prototype carrier for
other water-soluble therapeutic agents. In the first section, PFC double emulsions
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containing fluorescein - a hydrophilic fluorophore - are prepared and studied to
demonstrate the proof-of-concept that fluorescein encapsulation within a PFC double
emulsion delays its release until US exposure. The ability of ADV to release the
encapsulated fluorescein is also evaluated. In the second section, the encapsulation
of a chemical embolic agent, thrombin (factor IIa) - a serine protease in the
coagulation cascade that converts fibrinogen into fibrin - is explored using different
emulsification techniques. The effects of the various techniques are studied in terms
of the resulting emulsion, with a focus on thrombin stability and retention. ADV of
the thrombin-loaded emulsion is achieved using ultrasound parameters suitable for
in vivo applications.
4.2 Materials and Methods
4.2.1 Fluorosurfactant synthesis
The copolymer used to stabilize the primary emulsion (W1/PFC) was synthesized
using a two-step process, as seen in Fig. 4.1 and outlined in Holtze et al. [38].
First, Krytox 157 FSL (DuPont, Wilmington, DE, USA) - a perfluoroether with
carboxylic acid functionality - was converted to an acid chloride using methods
previously described [39; 40]. Briefly, under a nitrogen purge, Krytox 157 FSL
was added to a round bottom flask containing HFE-7100 (3M, St. Paul, MN,
USA), a mixture of methyl nonafluoroisobutyl ether and methyl nonafluorobutyl
ether. Thionyl chloride (Sigma Aldrich, St. Louis, MO, USA) was then added in
a 10:1 molar excess relative to the Krytox 157 FSL. The flask was refluxed with
a condenser and stirred for 24 hours at 50◦C while under a nitrogen purge. The
resulting mixture was concentrated using a rotary evaporator. Second, the acid
chloride was reacted with polyoxyethylene (PEG) diamine (Sigma Aldrich) to form
a copolymer, analogous to previously described methods [39; 40]. The solvent was
a 5:3 volumetric ratio of HFE-7100 and benzotrifluoride (Alfa Aesar, Ward Hill,
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MA, USA). Similar experimental conditions were used as in the first reaction step.
The resulting copolymer, termed Krytox-PEG copolymer, was concentrated using





















































Figure 4.1: The Kytox 157 FSL is first converted into an acid chloride and then
reacted with PEG-diamine to form a copolymer via amide linkages.
4.2.2 Fluorescein emulsion preparation
The primary emulsion was formed by first dissolving, in a 1.5 mL centrifuge tube
(Thermo Fisher Scientific, Waltham, MA, USA), Krytox-PEG copolymer (6 mg/mL
PFC) in 400 µL of either pefluoro-n-pentane (PFP, Alfa Aesar) or perfluoro-n-hexane
(PFH, Alfa Aesar). Next, 200 µL of a 100 mg/mL solution of fluoroscein sodium salt
(Sigma Aldrich) in normal saline (0.9% w/v, Hospira Inc., Lake Forest, IL, USA)
was added to the PFC phase. The mixture was emulsified, while in an ice bath,
via sonication using a microtip (model 450, 20 kHz, 3.2 mm diameter, Branson,
Danbury, CT, USA) operating at 125 W/cm2 for 30 seconds in continuous mode. In
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a 2 mL glass vial (Shamrock Glass, Seaford, DE, USA), 250 µL of primary emulsion
was then added to 750 µL of a 10 mg/mL solution of Pluronic F-68 (Poloxamer 188,
Sigma Aldrich) dissolved in normal saline. The vial was sealed with a rubber stopper
and metal cap and subsequently shaken for 45 seconds at 4550 cycles per minute
using an amalgamator (VialMix, Lantheus Medical Imaging, Billerica, MA, USA).
The resulting double emulsion was used immediately after processing, though it was
confirmed that the emulsion was stable, in terms of encapsulation efficiency and
droplet size distribution, for at least 24 hours if stored at 5◦C . Table 4.1 summarizes
the fluorescein emulsions and associated processing parameters.
Table 4.1: Summary of fluorescein and thrombin emulsions used for studies. In all
cases, the primary emulsion was formed using sonication.
Formulation Compound PFC Processinga
F1 fluorescein PFP shaking
F2 fluorescein PFH shaking
T1 thrombin PFP sonication
T2 thrombin PFP shaking
T3 thrombin PFP stirring
T4 thrombin PFP stirring + glass beads
T5 thrombinb PFP stirring + glass beads
aDuring second emulsification step
bXanthan gum dissolved in the W1 phase
4.2.3 Thrombin emulsion preparation
Thrombin (Thrombin-JMI, bovine-origin, King Pharmaceuticals, Bristol, TN,
USA) was dissolved in normal saline at a concentration of 5000 international units
(IU) per mL. In a microcentrifuge tube, 300 µL of thrombin solution was combined
with 650 µL of PFP, which already contained dissolved Krytox-PEG copolymer
(6 mg/mL PFC). The mixture was then sonicated, as previously described for the
fluorescein emulsions, to form the primary emulsion. The primary emulsion (475
µL) was combined with a 10 mg/mL solution of Pluronic F-68 in saline (1200
µL) and emulsified to form the double emulsion. Three processing techniques
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were explored for the second emulsification step: sonication, shaking, or magnetic
stirring. For emulsification via sonication, the primary emulsion was added to a
microcentrifuge tube along with the Pluronic F-68 solution and then sonicated as
previously described. For emulsification via shaking, the primary emulsion and
Pluronic F-68 solution were added to a 2 mL glass vial and processed similarly to
the second emulsification step of the fluorescein emulsions. For emulsification via
magnetic stirring, the primary emulsion was added to the Pluronic F-68 solution,
contained in a 2 mL glass vial, while being stirred at 1100 rpm for 15 minutes. The
vial was placed in an ice bath during the stirring process. Borosilicate glass balls (2
mm diameter, Chemglass Inc., Vineland, NJ, USA) were added in two formulations
(T4 and T5) to reduce the droplet size during the stirring step. Xanthan gum (Sigma
Aldrich) was dissolved in the thrombin solution (10 mg/mL) in one formulation (T5)
in order to increase the viscosity of the encapsulated aqueous phase; this was done
in an effort to decrease the mobility of the thrombin in the W1 phase and hence the
diffusion rate of thrombin from the emulsion [41]. All experiments were conducted
with emulsions that had been processed immediately prior to use, though it was
confirmed that the emulsions were stable, in terms of encapsulation efficiencies and
droplet size distributions, for at least 24 hours if stored at 5◦C. Table 4.1 summarizes
the various thrombin formulations that were investigated.
4.2.4 Physical characterization of emulsions
The structures of the double emulsions containing fluorescein were determined
using visible and fluorescent microscopy. Visible micrographs of the thrombin
emulsions were also taken. The emulsions were diluted in normal saline and images
were taken using a microscope (Leica DMRB, Bannockburn, IL, USA) and camera
(Spot FLEX, Diagnostic Instruments Inc., Sterling Heights, MI, USA), controlled by
Spot Advanced software (Diagnostic Instruments Inc.). The emulsions were sized
using a Coulter counter (Multisizer 3, Beckman Coulter Inc., Fullteron, CA, USA).
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Prior to sizing, the emulsions were diluted in normal saline that had been filtered
through a 0.22 µm filter (GSWP, Millipore, Billerica, MA, USA). All formulations
were sized using a 50 µm aperture, which can count particles between 1.0-30 µm.
The T3 formulation was also sized with a 140 µm aperture, which can count particles
between 2.8-84 µm, due to the presence of larger droplets.
4.2.5 Encapsulation efficiency of fluorescein emulsions
The fluorescein emulsions were washed in triplicate to remove unencapsulated
fluorescein. Due to the densities of PFP (1.6 g/mL) and PFH (1.7 g/mL), the washing
was accomplished by centrifuging the droplets at 1200 rpm for 3 minutes. Repeated
centrifugation did not cause significant droplet breaking, which was confirmed by
measuring the fluorescein concentration in the supernatant between the second and
third washings. The concentration of encapsulated fluorescein was determined by
adding an aliquot of the washed emulsion to methanol (CHROMASOLV Plus for
HPLC, Sigma Aldrich), thereby breaking the emulsion. The fluorescein concentration
was determined via fluorescence spectroscopy (LS-50B, PerkinElmer, Waltham, MA,
USA) with excitation and emission wavelengths of 485 nm and 525 nm, respectively.
The encapsulation efficiency was calculated as the ratio of encapsulated fluorescein
to the initial amount of fluorescein loaded into the emulsion (i.e. prior to washing).
4.2.6 In vitro fluorescein release
Fluorescein release from the PFP and PFH emulsions was measured using a
Franz diffusion cell (PermeGear, Inc., Hellertown, PA, USA). A cellulose membrane
(6-8 kDa molecular weight cutoff, Spectrum Laboratories, Inc., Rancho Dominguez,
CA, USA), soaked in normal saline 30 minutes prior to use, was mounted between
the donor and receptor compartments. By comparison, the molecular weight of
the ionized form of fluorescein is 328.3 Da. The donor media consisted of 2 mL
of fluorescein emulsion, washed in triplicate to remove unencapsulated fluorescein.
93
The receptor media consisted of 7.5 mL of normal saline. Near sink conditions
were maintained in the receptor compartment throughout the experiment, with the
fluorescein concentration in the receptor compartment never exceeding 0.01% of
saturation. . The diffusion area between both compartments was 1.77 cm2. The
stirring rate and temperature in the receptor compartment were kept at 600 rpm and
37◦C, respectively. Note that for F1, the temperature inside the receptor is above
the boiling point of PFP whereas for F2 the receptor is below the boiling point of
PFH. In order to prevent settling of the emulsion onto the membrane, due to the
densities of PFP and PFH, an overhead stirrer operating at 600 rpm was used in the
donor compartment. At 15-minute intervals, aliquots of the receptor medium were
withdrawn and immediately replaced with an equal volume of fresh, normal saline.
The amount of fluorescein released was determined via fluorescence spectroscopy as
previously described.
To determine the effect of ADV on fluorescein release, the PFP and PFH
emulsions were placed in 15 mL centrifuge tubes (Thermo Fisher Scientific) and
immersed in a water bath heated to 37◦C and 64◦C, respectively. In each case,
the emulsion was warmed to 8◦C of superheat since the normal boiling points of
PFP and PFH are 29◦C and 56◦C, respectively. The emulsions were continuously
sonicated for 2 minutes using the microtip operating at 20 kHz and 312 W/cm2
in order to generate ADV. Low frequency, continuous wave US, which is difficult
to focus in vivo, was used to generate ADV - compared to previous studies which
used higher frequency (1-10 MHz), pulsed US [17; 23; 26; 27; 42; 43] - to maximize
the cavitation-assisted vaporization of the emulsion during these proof-of-concept
studies. The resulting mixture (post-sonication) was then added to the donor
compartment of the diffusion cell and the fluorescein release was determined as
previously described. The fluorescein release rates from the emulsion studies were
compared to mass fluxes obtained when an equal concentration of fluorescein solution
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was loaded into the donor compartment. The volume fraction of droplets vaporized
after ADV was determined by counting the droplets remaining in the tube post US
exposure versus a control case (i.e. without US) with a Coulter counter [17]. The
droplet sample was briefly over-pressurized in a gas-tight syringe in order to destroy
existing microbubbles and decrease the likelihood of counting these as droplets.
4.2.7 Encapsulation efficiency and stability of thrombin
emulsions
The encapsulation efficiency of the thrombin double emulsions, immediately
following the second emulsification step, was determined by separating the droplets
from the continuous, aqueous phase via repeated centrifugation using similar
methods as for the fluorescein emulsions. Minimal droplet breakage, assessed as
previously described for the fluorescein emulsions, occurred during the washing
steps. The non-encapsulated thrombin concentration was estimated using the Pierce
660 nm protein assay (Thermo Fisher Scientific) and the encapsulation efficiency
was determined as previously described. The stability of the thrombin encapsulation
in the emulsions was determined by heating the emulsion to 37◦C while stirring at
1100 rpm. At 15-minute intervals, aliquots were removed, centrifuged to separate
the droplets from the continuous phase, and the non-encapsulated thrombin
concentration was estimated as previously stated.
4.2.8 In vitro thrombin release
Thrombin release from the emulsions, in blood, was assessed using a modified
activated clotting time (ACT) assay. Fresh, whole canine blood was acquired and
immediately mixed with citrate-phosphate-dextrose (CPD) solution (Sigma Aldrich),
an anticoagulant, in a volumetric ratio of 10:1.4, respectively. CPD, used in the
storage of whole blood, prevents coagulation via the chelation of calcium ions with
citrate [44]. The blood was stored at 4◦C and used within 7 days of acquisition.
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All protocols involved in the blood acquisition were approved by the University of
Michigan Committee on the Use and Care of Animals (UCUCA).
The effect of thrombin concentration on the ACT was determined as follows.
First, 0.4 mL of blood containing CPD was added to a plastic, ACT test tube
(International Technidyne Corporation, Edison, NJ, USA), which contained
approximately 30 mg glass beads (119.6 µm mean diameter) and a magnet. Then,
an aliquot of thrombin solution was added to the tube. The volume of thrombin
added never exceeded 50 µL. Finally, the tube was capped, gently mixed, and placed
into the Hemochron 400 (International Technidyne Corporation). The instrument
mechanically detected the formation of a fibrin clot via the rotation of the magnet
within the tube. Upon clotting, the magnet lifted within the tube; the time for
this to occur was the ACT. Due to the possibility of thrombin denaturation or loss
of activity during the emulsion processing, thrombin solutions were subjected to
identical processing conditions, as seen in Table 4.1. These solutions were tested
for thrombin activity using the ACT assay. Additionally, due to the antithrombotic
properties of Pluronic F-68 [45; 46], each emulsion component - Pluronic F-68, PFP,
and Krytox-PEG copolymer - and the blank emulsion (i.e. without thrombin) were
combined with a known concentration of thrombin to determine its effect on the
ACT. The ACT was measured with each thrombin emulsion as well.
To determine the effect of ADV on thrombin release, each emulsion was injected
into an OptiCellTM(Thermo Fisher Scientific) chamber and exposed to US using
a previously utilized experimental setup [17]. The chamber was placed into an
OptiCellTMholder that was located within a tank (40 × 60 × 27 cm) containing
degassed, deionized water heated to 37◦C. The surface of the tank water was covered
with air-filled plastic balls (Cole-Parmer Inc., Vernon Hills, IL, USA) to minimize
regassing and heat loss as well as scattering the reflected US at the air/water surface.
A calibrated 3.5 MHz single-element transducer (1.9 cm diameter, 3.81 cm focal
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length, A381S, Panametrics, Olympus NDT Inc., Waltham, MA) was positioned
below the chamber and focused on the bottom window of the chamber. Acoustic
pulses generated by the transducer - 3.7 µs pulse duration, 10 ms pulse repetition
period (PRP), 4.7 MPa peak rarefactional pressure, 11.3 MPa peak compressional
pressure - were achieved using a function generator (33120A, Agilent Technologies,
Palo Alto, CA, USA) and power amplifier (55 dB, model A-300, E & I, Rochester,
NY, USA). The transducer was rastered via a computer-controlled positioning
system, at 4 mm/s across the chamber surface in order to vaporize the emulsion.
Due to the volume of emulsion introduced into the OptiCellTM(1 mL), only a fraction
of the chamber surface was covered by the emulsion and subsequently insonified.
The raster spacing was 0.5 mm; by comparison, the -6 dB lateral beam width of the
transducer was 0.88 mm. The total exposure time was 5 minutes. Following the US
exposure, the mixture was removed from the OptiCellTMand the ACT was measured
as described previously. The volume fraction of droplets vaporized was determined
by counting the droplets remaining in the OptiCellTMpost US exposure versus a
control case (i.e. without US) with the Coulter counter, as described previously for
the fluorescein emulsions.
4.2.9 Statistical analysis
Each experimental value is expressed as mean ± standard deviation and the
result of at least three independent measurements. Statistically significant differences
between experimental groups was determined using a Student’s t-test. A significance
level of 0.01 was used for all comparisons.
97
4.3 Results
4.3.1 Physiochemical characterization of fluorescein emul-
sions
Representative micrographs of the fluorescein emulsions are displayed in Fig. 4.2.
The aqueous droplets containing fluorescein (W1), stabilized by the Krytox-PEG
copolymer, are surrounded by PFC. The fluorescein droplets comprise a large
volume fraction and are homogenously distributed within the PFC globule. Similar
structures were observed for the thrombin emulsions. As seen in Table 4.2, the mean
diameter of fluorescein emulsions containing PFP and PFH - F1 and F2, respectively
- were not statistically different. Additionally, the encapsulation efficiencies for F1
and F2 were not statistically different either.
Figure 4.2: Micrographs of a W1/PFC/W2 emulsion containing fluorescein in the
W1 phase. The left image is an overlay of both visible and fluorescent micrographs.
The scale bar is 8 µm. The structure of the W1/PFC/W2 emulsion - water droplets
containing fluorescein within a globule of PFC - can be clearly seen in the right image,
which displays a 100 µm diameter globule.
4.3.2 In vitro release of fluorescein
The retention of fluorescein within the emulsions, as evaluated using a Franz
diffusion cell, is shown in Fig. 4.3. The values in Fig. 4.3 were corrected for
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Table 4.2: Characterization of fluorescein and thrombin emulsions. Thrombin precipi-
tation, during the second emulsification step, and subsequent inactivation of thrombin
during ADV was suspected in T2.
Formulation Mean Percent of droplets Percent (%) Volume Percent (%) change
diameter >6 µm encapsulation percent in ACT
(µm) Number Volume vaporizeda upon ADVb
F1 2.5 ± 0.1 4.3 ± 1.3 53.1 ± 9.4 5.4 ± 1.0 100 NA
F2 2.4 ± 0.2 2.6 ± 1.8 32.3 ± 15.4 3.8 ± 1.1 100 NA
T1 1.6 ± 0.1 0.04 ± 0.02 6.7 ± 3.0 76.3 ± 3.4 10.2 ± 4.2 -7.4 ± 1.6
T2c 2.6 ± 0.2 6.5 ± 1.4 83.2 ± 1.0 63.7 ± 22.9 25.6 ± 7.1 63.0 ± 12.2
T3 27.4 ± 5.9 89.2 ± 1.1 99.9 ± 0.1 97.5 ± 0.6 100 -78.0 ± 13.5
T4 3.5 ± 0.1 15.5 ± 0.8 89.4 ± 4.5 98.8 ± 1.1 28.7 ± 10.2 -23.3. ± 5.9
T5 3.9 ± 0.1 17.6 ± 0.5 88.9 ± 3.1 97.2 ± 0.5 34.3 ± 15.9 -19.0 ± 4.9
aCases where complete vaporization was observed, and thus the number of droplets
remaining in solution after ADV is below the noise threshold of the Coulter counter,
are denoted by ‘100’.
bExcept for T1, all changes in the ACT were statistically significant.
cParameters affected by thrombin precipitation include percent encapsulation and
percent change in ACT upon ADV.
the aliquots of solution and hence fluorescein mass removed during sampling. An
aqueous solution of fluorescein, equal in concentration to each emulsion, was used
as a control. It was confirmed, by mixing blank emulsion (i.e. without fluorescein)
and fluorescein solution, that the presence of droplets within the donor compartment
did not statistically change the fluorescein diffusion across the membrane for the
fluorescein in solution. Therefore, the encapsulation of fluorescein within the
emulsion delayed its release, as is evident in Fig. 4.3, relative to the fluorescein
solution.
The fluorescein flux was calculated based on a linear regression of the data
between 15 and 60 minutes, which yielded squared correlation coefficients (R2)
greater than 0.95 in all cases. The fluxes for F1 and F2 were 0.19 ± 0.02
µg/cm2/min and 0.07 ± 0.01 µg/cm2/min, respectively. Note that the concentration
of encapsulated fluorecein in F1 is higher than F2, 0.6 mg/mL versus 0.3 mg/mL.
By comparison, when F1 and F2 are exposed to US and fluorescein is released via
ADV, the fluxes increase to 1.12 ± 0.24 µg/cm2/min and 0.60 ± 0.04 µg/cm2/min,
respectively. This corresponds to a 5.7 ± 1.4 and 8.2 ± 1.3 fold increase in flux
for F1 and F2, respectively. These fluxes are not statistically different than the
fluxes obtained for fluorescein solutions of equal concentration. This is expected
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Figure 4.3: In vitro release profiles of PFP (left) and PFH (right) double emulsions
containing fluorescein at 37◦C. In each case, the release profiles obtained from the
emulsion, with and without ADV, are compared to a solution of fluorescein of equal
concentration. The fluorescein concentration for the PFP and PFH emulsions are 0.6
mg/mL and 0.3 mg/mL, respectively.
considering that all of the droplets had been vaporized as a result of ADV, as seen
in Table 4.2.
4.3.3 Physiochemical characterization of thrombin emulsions
Table 4.2 lists the mean diameters for the five different thrombin emulsions
(T1-T5). The percent of droplets greater than 6 µm diameter, in terms of both
number and volume, are included to indicate how suitable the emulsions are for
intravenous administration. The percent of thrombin encapsulation is also included
in Table 4.2. T1, processed via sonication during the second emulsification step,
yielded the smallest mean diameter (1.6 µm). The shaken formulation, T2, yielded
a mean diameter (2.6 µm) that was not statistically different than the similarly
processed fluorescein emulsions (F1 and F2). Alternatively, T3 - processed via
stirring - yielded the largest mean diameter (27.4 µm). The addition of glass beads,
in an effort to increase the shear force generated during stirring, caused the mean
diameters of T4 and T5 to decrease to 3.5 µm and 3.9 µm, respectively.
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The thrombin emulsions were initially loaded with a thrombin concentration of
417 IU/mL. The largest encapsulation efficiencies were obtained for the emulsions
that were stirred in the second emulsification step (T3-T5). The second emulsification
step is critical when forming double emulsions since excess shear or mixing can cause
the W1 phase of the primary emulsion (i.e. W1/PFC) to coalesce with the external
aqueous phase (i.e. W2) [47]. Therefore, emulsification techniques that generate
lower shear forces, such as stirring, are amenable in the second emulsification
step [48]. Pair-wise comparisons between T3, T4, and T5 indicate no statistically
significant differences in the encapsulation efficiencies. Thus, in the case of T4, the
addition of glass beads decreased the droplet size without compromising thrombin
encapsulation. Additionally, increasing the viscosity of the W1 phase more than
1000x fold [49], as in T5, did not affect the encapsulation efficiency. As will be
discussed in the next section, the encapsulation efficiency of T2 is skewed by the
denaturation of thrombin during the second emulsification step. Upon warming the
thrombin emulsions to 37◦C and stirring simultaneously, no statistically significant
changes were observed in the encapsulation efficiency over a 1-hour period for any of
the thrombin emulsions.
4.3.4 Formulation parameters affecting thrombin activity
Figure 4.4 displays the measured ACT for different thrombin levels. The data was
fit (R2 > 0.94) using a sigmoidal curve used in previous works [17; 42]. There were
no statistically significant differences with the ACT data between 2.4 IU/mL and 24
IU/mL. Due to the susceptibility of proteins to aggregate, denature, or lose activity
during encapsulation processes [50], the thrombin activity was measured - in terms
of ACT - for thrombin solutions that had been subjected to sonication, shaking, or
stirring. No statistically significant differences were observed in ACT, compared to
the data in Fig. 4.4, when the thrombin solution was sonicated, shaken, or stirred.
For the sonicated and stirred cases, the thrombin solution was placed in an ice
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bath during the processing and no significant temperature increase was measured
throughout the processing. For the shaken case, the thrombin solution was chilled to
0◦C prior to shaking; the temperature of the thrombin solution inside the sealed vial,
measured using a needle-type thermocouple inserted through the rubber stopper,
was 30◦C after shaking. By comparison, human thrombin begins to denature above
45◦C [51]. Processing the thrombin solution twice, as seen in Table 4.1 for T1-T5,
yielded no statistically significant differences, relative to Fig. 4.4, except in the case
of T2 (i.e. sonication followed by shaking), where an approximate 300% increase in
ACT was observed. This increase in ACT was attributed to thrombin precipitation,
as confirmed visually and also with the colorimetric protein assay. Interestingly,
switching the processing order (i.e. shaking followed by sonication) did not cause a
statistically significant difference in the ACT.
Figure 4.4: Reference curve displaying the activated clotting time (ACT) for ca-
nine blood, stored with citrate-phosphate-dextrose (CPD) solution, as a function of
thrombin concentration.
Each emulsion component - Krytox-PEG copolymer, PFP, and Pluronic F-68
- along with the blank emulsion was combined with a known concentration of
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thrombin (in solution) to determine its effect on the ACT. The addition of PFP,
up to 1000x greater in concentration relative to the emulsions, did not cause a
statistically significant difference in the ACT. Pluronic F-68, a polymer with known
antithrombotic properties [45; 46] even in the presence of weak coagulation agonists,
did not produce a statistically significant difference in the ACT when added at
concentrations up to 100 mg/mL, which is 10x greater than the concentration used for
the emulsions. This is likely due to the use of thrombin, which is a strong coagulation
agonist, to form clots. As seen in Fig. 4.5, blank emulsions produced with increasing
levels of Krytox-PEG copolymer did produce a statistically significant increase in the
ACT. The introduction of low concentrations of compolymer (i.e. ≤ 0.018 mg/mL
blood) did not significantly change the ACT, but a very large change (i.e. > 1100%
increase) was observed at higher Krytox-PEG copolymer concentrations (i.e. ≥ 0.05
mg/mL blood). No statistically significant differences were observed in mean droplet
diameter or droplet number density (i.e. number of droplets per mL emulsion) across
the range of tested Krytox-PEG copolymer concentrations. Therefore, the thrombin
emulsions used for subsequent experiments, including for the data generated in Table
4.2, were formulated using low concentrations of Krytox-PEG copolymer.
4.3.5 In vitro release of thrombin
The validation of ADV-triggered release of thrombin from double emulsions was
determined using the ACT assay. As an indicator of thrombin retention within
the emulsion, the goal was to maximize and minimize the ACT without and with
ADV, respectively. Conceptually, the former goal translates into an infinite ACT for
the case where thrombin is highly retained in the emulsion due to the presence of
CPD in the blood. The latter goal, as seen in Fig. 4.4, corresponds to an ACT of
approximately 22 seconds. Figure 4.6 displays the ACT obtained for each thrombin
emulsion listed in Table 4.2 with and without ADV. For 4 out of 5 formulations,
T1 and T3-T5, a decrease in ACT was observed when the emulsion was exposed
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Figure 4.5: Anticoagulative effect of the Krytox-PEG copolymer used in the thrombin
emulsions. A blank emulsion, containing copolymer was mixed with thrombin solu-
tion. An aliquot of the resulting mixture, containing 1 IU thrombin, was added to
blood containing CPD. Points marked with an asterisk (*) indicate copolymer levels
that are not statistically different than control case (i.e. without copolymer).
to US, compared to the case without US; 3 out 5 formulations (T3-T5) exhibited
decreases that were statistically significant. Upon US exposure, T2 displayed an
increase in ACT compared to the case without US. The largest and smallest ACT,
prior to US exposure, were exhibited by T3 and T4, respectively. T3 displayed the
smallest ACT and largest absolute percent change in ACT after ADV. A higher
ACT (without ADV case) was observed for T5 (with xanthan gum) relative to T4
(without xanthan gum), though the percent change in ACT upon ADV was not
statistically different for T4 and T5. Additionally, as indicated in Table 4.2, the
droplets in T2 were completely vaporized after ADV. Table 4.3 shows the thrombin
concentration in blood, with and without ADV, calculated using the sigmoidal fit in
Fig. 4.4 and the ACT values in Fig. 4.6. The values in Table 4.3 are smaller than
the theoretical thrombin concentration (46.3 IU/mL), assuming the complete release
of thrombin from the emulsion and no inactivation.
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Figure 4.6: The effect of ADV (3.5 MHz, 3.7 µs pulse duration, 10 ms PRP, 4.7
MPa peak rarefactional pressure, 11.3 MPa peak compressional pressure, 5 minute
exposure) on the ACT for five different thrombin formulations. Cases where the ACT
was statistically different after ADV are denoted by an asterisk (*).
Table 4.3: The thrombin concentration in blood, estimated from the regression in Fig.
4.4 and the data from Fig. 4.6. The thrombin concentration, assuming the complete
release of thrombin from the emulsion and no inactivation, should have been 46.3
IU/mL.
Thrombin (IU/mL blood)
Formulation without ADV with ADV
T1 0.5 ± 0.05 0.6 ± 0.09
T2 0.4 ± 0.03 0.2 ± 0.01
T3 0.3 ± 0.03 3.1 ± 0.4
T4 0.8 ± 0.01 1.1 ± 0.7
T5 0.5 ± 0.02 0.6 ± 0.02
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4.4 Discussion
This study focuses on the development of PFC double emulsions that carry a
water-soluble payload and release the payload upon ADV. In general, the coupling
of drug release with ADV has three potential therapeutic advantages, beyond the
advantages previously described for US-triggered drug delivery; these synergisms
are unique to therapies involving ADV and build upon previous studies involving
ADV-induced vascular occlusion [26–28]. First, the simultaneous release of a
chemical embolic agent, such as thrombin, upon ADV can be used to sustain an
ADV-generated microbubble embolization. Second, the ischemia generated by
vascular occlusion could increase the residence time of a therapeutic agent within the
occluded tissue region, potentially increasing the amount of agent that diffuses into
the tissue. Third, prolonged ischemia can generate hypoxia, which could be used to
activate water-soluble, bioreductive prodrugs, such as NLCQ-1 [52], encapsulated
within the emulsion.
Due to the extremely hydrophobic and lipophobic qualities of PFCs [16], the
choice of surfactants suitable for stabilizing reverse PFC emulsions (i.e. W/PFC)
are quite limited [38; 53]. The synthesized Krytox-PEG copolymer enabled the
formation of a stable primary emulsion (W1/PFC) compared to primary emulsions
prepared using the unmodified Krytox. This is likely due to the presence of the
hydrophilic PEG group that stabilizes the W1/PFC interface [54]. The use of a
non-ionic hydrophilic group minimizes potential interactions between the surfactant
and charged therapeutic agents, such as proteins, which could lose biological
activity while encapsulated in the W1 phase [55]. Similarly structured Krytox-PEG
copolymers have displayed favorable biocompatibility properties when used to
encapsulate mammalian cells or small multicellular organisms within aqueous
microcompartments surrounded by PFC [38; 56].
The PFC layer separating the payload containing W1 phase from the exterior
106
W2 phase serves a dual purpose. First, the PFC acts as a diffusion barrier, thereby
preventing the inward or outward diffusion of material, such as the payload, from
the W1 phase; this is clearly seen, for example, in Fig. 4.3 and with the calculated
fluxes for F1 and F2. The minimization of payload diffusion from the emulsion is
important in order to couple payload release with ADV of the emulsion. Since the
viscosities of PFP (0.64 mPa·s) and PFH (1.11 mPa·s) are close to that of saline
(i.e. W1 phase), the barrier property of the PFC phase is likely attributed to the
hydrophobic and lipophobic properties of the PFC [16] and not caused by any
restriction in payload diffusion due to the PFC viscosity [41]. Second, the PFC phase
vaporizes upon ADV, thereby releasing the W1 phase into the W2 phase. Since the
ADV threshold scales inversely with degree of PFC superheat when the degree of
superheat is negative [42], low boiling point liquids should be used as the vaporizable
phase of the emulsion in order to minimize the acoustic energy required for ADV to
occur at normal body temperature. Straight-chain PFCs, such as PFP, meet this
boiling point requirement along with being biocompatible and inert [16]. Previous
studies with PFC droplets [42] and PFC droplets containing an oil layer [18; 19]
demonstrated an increase in mean droplet size as the boiling point, and hence
viscosity, of the PFC phase increased. An increase in the dispersed phase viscosity
is known to cause an increase in particle size [57]. Since F1 and F2 - composed of
PFP and PFH - respectively, possessed mean diameters that were not statistically
different, this may imply that the volume fraction of PFC within each globule is
relatively small such that the globule viscosities of F1 and F2 are similar.
Currently, the primary clinical use of thrombin is topical hemostasis [58]. The
intravascular use of thrombin has been limited to procedures where thrombin is
administered via a catheter, as in the treatment of pseudoaneurysms [36; 37],
due to the risk of mortality associated with extensive intravascular clotting. The
encapsulation of thrombin within a PFC emulsion and its subsequent release
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upon ADV could enable the targeted formation of thrombi within the vasculature.
Additionally, due to the short (< 15 s) half-life of thrombin in human plasma [59],
a colloidal thrombin formulation could increase the stability of the administered
thrombin [60–62].
Thrombin activity, as measured via the ACT assay, was maintained during
all emulsification steps except in the case of T2 (sonication followed by shaking).
Structural changes, denaturation, and loss of activity can occur when proteins
are exposed to US [63] or high shear rates [64]. Thus, sonication (under chilled
conditions) may have rendered the thrombin more susceptible to denaturation during
shaking, where a temperature increase and high shear stresses were generated.
Interestingly, the reverse processing conditions were not harsh enough to reduce the
thrombin activity. In addition, thrombin activity was impacted by the presence of
high levels of the synthesized, Krytox-PEG copolymer (Fig. 4.5). In this study,
Pluronic F-68, a polymer with known antithrombotic properties [45; 46], did not
alter the ACT in the presence of thrombin. Pluronic F-68 can become embedded into
the cell membrane of platelets, thereby inhibiting platelet aggregation by sterically
hindering interactions between platelets and lowering interfacial tension [45]. Due
to the structural similarities between the Krytox-PEG copolymer and Pluronic
F-68, it is possible that the mechanism causing an inhibition in platelet aggregation
is similar in both cases. When the emulsions with high Krytox-PEG copolymer
concentrations were washed in triplicate (via centrifugation), the obtained ACTs
were not statistically different from the control case. This observation, combined
with the statistically constant droplet diameter and number density across the range
of Krytox-PEG copolymers tested, suggest that excess copolymer was present when
the concentration exceeded 0.05 mg/mL blood.
The thrombin emulsions displayed higher percent encapsulations than the
fluorescein emulsions. This may be due to the smaller osmotic pressure difference
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across the W1/W2 phases of the thrombin emulsion. Large differences in osmotic
pressure can cause the rapid breakdown of double emulsions to simple emulsions
(i.e. PFC/W) [65]. Despite the stable retention of thrombin within the emulsions
over a 1-hour period, some thrombin was released from the emulsions in the absence
of US during the ACT measurements (Fig. 4.6). However, due to the high loading
of thrombin within the emulsions (417 IU/mL), the release of a small amount
of thrombin could alter the ACT (Figs. 4.4 and 4.6). This release could have
been facilitated by the movement of the magnet over the glass beads in the ACT
tube, thereby grinding the droplets. In vitro studies have indicated that less than
0.1 IU/mL thrombin is required to trigger the onset of clot formation whereas
the concentration of free thrombin during a coagulation reaction ranges from less
than 0.1 IU/mL to greater than 11.5-57.5 IU/mL [66]. Comparatively, the normal
concentration of prothrombin (factor II), the inactive precursor of thrombin, is
approximately 1.3 IU/mL in adult humans [67]. As seen in Fig. 4.6 and Table 4.2,
T3 displayed the largest and smallest ACT values before and after ADV, respectively.
Thrombin was most highly retained in T3 before ADV, whereas ADV caused a
ten-fold increase in the amount of thrombin released (Table 4.3). Due to a larger
mean diameter of T3 (27.4 µm) relative to the other thrombin formulations, T3 is
most amenable to intraarterial administration, similar to double emulsions utilized
in the treatment of hepatocellular carcinoma [68].
The effect of ADV on protein stability, specifically proteins released from PFC
emulsions via ADV, is currently unknown. Previous work [42] demonstrated that
ADV can occur independently of inertial cavitation, a mechanism that can induce
molecular damage. The volume percent of droplets vaporized (Table 4.2) was larger
than the percent of thrombin released estimated using the concentrations in Table
4.3. For example, 28.7% (by volume) of T4 was vaporized as a result of ADV, but
only 2.4% of the thrombin was released based on the measured ACT. As seen in Fig.
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4.4, the ACT levels off for thrombin concentrations higher than 10 IU/mL; thus the
ACT cannot be used to calculate high thrombin concentrations, such as that which
would be obtained theoretically if complete thrombin release from the emulsion were
to occur (46.3 IU/mL). Even with this consideration, the large difference between
the volume percent of droplets vaporized and the percent of thrombin released
could indicate that ADV is inactivating the thrombin, especially considering the
rapid consumption of PFC observed during ADV [43]. Precipitated thrombin - an
indicator of thrombin inactivation - was not seen with T3 after ADV, despite the
complete vaporization of the emulsion; due to the partial vaporization of the other
formulations, it was not possible to observe precipitated thrombin. Previous studies
[17] focusing on the release of a small molecular weight compound (304.2 g/mol)
via ADV did not demonstrate molecular inactivation due to ADV. Large molecules,
such as thrombin (∼ 36000 g/mol), can experience broken chemical bonds due to the
shear forces generated by the rapid motion of solvent following cavitational collapse
[69]. Additionally, as seen for T2 (Fig. 4.6), ADV generated additional inactivation
of thrombin that had already been partially inactivated, which causes the ACT to
increase after droplet vaporization. The investigation of acoustic parameters that
would maximize thrombin release but minimize the apparent thrombin inactivation
are beyond the scope of this work.
4.5 Conclusions
PFC double emulsions can serve as carriers for water-soluble therapeutic agents.
These emulsions can be vaporized using US, thereby releasing the encapsulated
agent from the emulsions via ADV. The use of a Kytox-PEG copolymer, which
was found to have antithrombotic properties at higher concentrations, enabled the
stable formation of the primary emulsion. Both fluorescein and thrombin were
highly retained in the emulsions; ADV caused a statistically significant increase in
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fluorescein and thrombin release. The results also suggest that thrombin inactivation
may be occurring as a result of the ADV process. Future studies are focused
on understanding this inactivation, especially as it relates to ADV and inertial
cavitation, and demonstrating the synergisms of ADV and drug delivery in vivo.
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CHAPTER V
Conclusions and Future Work
5.1 Introduction
The work presented in chapters II through IV contributes to the development
of acoustic droplet vaporization (ADV) as a drug delivery mechanism. Compared
to vascular occlusion, the most extensively studied therapeutic application of ADV
[1–3], the use of ADV in drug delivery, which was initially proposed by Apfel [4], is
relatively new. Previous studies dealing with ADV and drug delivery have focused
on the formulation of drug-laden perfluorocarbon (PFC) emulsions [5–7]. However,
only limited efforts were concentrated on bridging the knowledge gap between
pharmaceutical and acoustical studies, especially interrelating the two fields. This
dissertation begins to address some of the important connections between the two
disciplines.
The two drug delivery applications highlighted in chapters III and IV display the
potential of ADV to produce minimally invasive chemoembolization and sustained
vascular occlusion, respectively. The use of PFC emulsions and ADV in drug delivery
provides many therapeutic advantages and synergisms not afforded by the more
widely studied microbubble delivery systems, thereby potentially increasing the
realizability of targeted drug delivery using ADV. PFC emulsions possess a longer
circulation half-life relative to microbubbles. Thus, the time available to perform
an acoustically enabled, targeted intervention or procedure is longer. Furthermore,
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systemic drug deposition due to colloidal dissolution is less of an issue with droplets
than with microbubbles. Droplets can also be stably formulated with submicron
diameters that can undergo extravasation within the leaky microvasculature of
tumors [8; 9]. Localized ischemia caused by ADV-generated microbubbles can
increase the residence time and potentially increase the absorption of drug within
the targeted area. As will be discussed later, the delivery of prodrugs activated via
hypoxia, itself generated by ADV, is another attractive option.
5.2 Experimental Conclusion
5.2.1 The Role of Inertial Cavitation in Acoustic Droplet
Vaporization
Chapter II investigated the role of inertial cavitation (IC) in ADV via the
measurement of the IC and ADV thresholds in an in vitro setup. A previous study
demonstrated that IC nuclei (i.e. US contrast agent) can lower the ADV threshold
[10]. Flowing droplets were exposed to pulsed ultrasound (US) from a focused, 3.5
MHz single element transducer. Simultaneously, broadband noise, characteristic of
IC, was detected using a passive acoustic detector; ADV, detected as an increase in
echogenicity, was simultaneously recorded using B-mode US. Bulk fluid, droplet, and
acoustic parameters known to influence each threshold were explored.
In all tested cases, the ADV threshold occurred at a lower rarefactional pressure
than the IC threshold, indicating that IC is not necessary to cause vaporization.
The ADV thresholds were not statistically different when measured in gas saturated
(170 mmHg O2 or 106.5% O2) and degassed (60 mmHg O2 or 37.6% O2) water, a
finding that is consistent with previous results [1]. When measured in heparanized
whole blood or water-glycerol mixtures, both thresholds increased relative to values
obtained in water due to the increase in bulk fluid viscosity. Interestingly, whole
blood and water-glycerol mixtures possess surface tensions that are lower than pure
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water. Thus, the direct correlation between the IC threshold and viscosity, and not
surface tension, suggests that the IC nuclei were not submicron in size [11] and likely
the gas bubbles generated by ADV.
The mean droplet diameter and dispersed phase viscosity, for PFC-in-water
(PFC/W) emulsions, were directly correlated across the homologous series of
straight chain PFCs (C5F12, C6F14, C8F18). For negative degrees of superheat
(i.e. the emulsion was not superheated), an inverse trend exists between both
thresholds and the degree of superheat, which is defined as the difference between a
given temperature and the boiling point of the PFC. The ADV and IC thresholds
remained statistically constant for positive degrees of superheat. For droplets
whose mean diameters were between 1 and 5 µm, the ADV threshold displayed an
inverse correlation with mean diameter between 1 and 2.5 µm; between 2.5 and 5.0
µm, the ADV threshold was relatively constant. Similarly, the IC threshold was
constant across the entire range of mean droplet diameters (1 - 5 µm). There were
no statistically significant differences in either threshold for droplets stabilized by
bovine serum albumin (BSA) or lipids.
Concerning pulse repetition frequency (PRF), droplets exposed to a single US
exposure displayed higher ADV and IC thresholds than droplets exposed to multiple
exposures. Increasing the PRF for droplets already exposed to multiple exposures
did not cause a change in either threshold. An inverse correlation existed between the
IC threshold and the pulse length; the ADV threshold was constant for microsecond
pulse lengths, which is consistent with previous results [10].
Overall, the results suggest that the nucleus for ADV is internal to a droplet and
the IC nucleus is the bubble generated by ADV. The latter point is supported by
an analytical model which estimates the minimum acoustic rarefactional pressures
required to produce IC as a function of bubble size [11].
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5.2.2 Delivery of Chlorambucil using an Acoustically-
Triggered, Perfluoropentane Emulsion
In chapter III, in vitro studies were completed that demonstrated the ability
of ADV to release an oil soluble drug encapsulated within an emulsion. The
work focused on the delivery of a chemotherapy drug which, combined with the
occlusive properties of ADV-generated microbubbles, could enable the development
of non-invasive chemoembolization. A double emulsion (PFC-in-oil-in-water,
PFC/O/W), suitable for intravenous administration, was formulated using soybean
oil, perfluoropentane (PFP), and BSA as the shell. Chlorambucil (CHL), a lipophilic
chemotherapy agent, was dissolved in the soybean oil. Optical studies indicated that
the fraction of PFP per droplet increased as the droplet diameter increased. The
ADV threshold of the dual phase droplets was higher, for a given mean diameter,
compared to single phase droplets (i.e. PFP/W) studied in chapter II. However,
when the mean diameter of the dual phase droplets was corrected for the oil layer,
thereby enabling the estimation of the PFP core diameter, the ADV thresholds of
the dual phase droplets were consistent with the thresholds obtained in chapter II.
A full factorial design of three parameters - droplets, CHL, and US - in two
levels (with or without) - was completed in order to assess the cellular growth
inhibition (GI) resulting from each combination. A 60-minute incubation with
CHL-laden droplets (100 µM) caused a 46.7% GI of Chinese hamster ovary (CHO)
cells, compared to 83.3% GI obtained with cells exposed to the same concentration
of CHL dissolved in dimethyl sulfoxide (DMSO). Thus, the cytotoxicity of CHL
decreased upon its encapsulation and subsequent retention within the emulsion.
Upon exposure to 6.3 MHz US, the CHL-laden droplets caused an 84.3% GI.
Therefore, ADV significantly increased the GI and hence CHL exposure experienced
by the cells. Comparatively, the ADV of sham droplets (i.e. without CHL) caused
a 22.6% GI, which was likely due to the ADV process itself and the deplating of
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cells by unvaporized droplets. All of these GI values reflect experiments where the
droplets were not in direct contact with the cells during treatment. ADV of droplets
in direct contact with CHO cells caused a 74.9% GI, a significant increase relative to
the cases where the droplets were not in direct contact. This initial investigation into
the cellular bioeffects of ADV revealed that the vaporization process could produce
cell detachment or death in vitro, though the two phenomena were inseparable
based on the methods used to calculate GI. The benefits of using an ADV-generated
occlusion to increase the residence time of a chemotherapy agent within a tumor
was seen by comparing the CHL concentration required to produce 50% GI for 15
minute (167 µM) and 60 minute (57 µM) exposures. Additionally, the mean CHO
cell diameter was shown to correlate with CHL exposure.
The ADV efficiency (i.e. the fraction of droplets that vaporize) was shown to
display a sigmoidal relationship as a function of droplet diameter, with a direct
correlation occurring between 2 and 12 µm (see Fig. 3.9). This is consistent with
the data obtained in chapter II (see Fig. 2.7) which displays an inverse relationship
between ADV threshold and droplet diameter. Thus, it appears that droplets with
a lower ADV threshold possess a higher ADV efficiency. Repeated US exposures
were shown to increase the ADV efficiency for a given droplet diameter, though the
incremental increase in efficiency was smaller as the number of exposures increased.
This suggests that a constant fraction of remaining droplets vaporize per exposure.
5.2.3 Delivery of Water-Soluble Drugs using Acoustically-
Triggered, Perfluorocarbon Double Emulsions
The utility of the ADV drug delivery formulation presented in chapter III was
expanded in chapter IV to include the encapsulation of water-soluble compounds. A
biocompatible, fluorophilic, triblock copolymer was synthesized which enabled the
formation of water-in-PFC-in-water (W1/PFC/W2) double emulsions. The double
emulsions in chapter IV, multiple water droplets surrounded by a globule of PFC,
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were distinct in structure from the PFC/O/W emulsions in chapter III, a single
PFC core surrounded by an oil layer. In the first series of studies, the retention of
fluorescein in the W1 phase was assessed using a Franz diffusion cell. The mass
fluxes of fluorescein in PFP and perfluorohexane (PFH) emulsions, measured over 60
minutes, was 17% and 12%, respectively, relative to cases where the emulsions were
exposed to 20 kHz US to generate ADV. Thus, the PFC layer within the double
emulsion hindered the diffusion of fluorescein from the W1 phase.
In the second series of experiments, thrombin - an enzyme involved in the
coagulation of blood - was incorporated into the W1 phase. The goal of this
work was to study the potential of extending the duration of an ADV-generated
embolization via the simultaneous generation of a clot within a targeted vessel.
Different processing techniques were explored during the second emulsification step
(i.e. emulsification of the primary emulsion to form the secondary emulsion) and
thrombin release from the emulsions was assessed using the activated clotting time
(ACT) assay. Thrombin inactivation was observed when the enzyme was subjected
to sonication followed by shaking. Additionally, high concentrations of copolymer
were noted to produce a substantial increase in the ACT, likely due to the interaction
of the copolymer with platelets. Thrombin was stably retained in four out of five
formulations tested. For three out of five formulations, the ACT of whole blood
decreased in a statistically significant manner when incubated with thrombin-loaded
emulsions exposed to 3.5 MHz US compared to emulsions not exposed to US. Thus,
ADV was shown to increase the release of thrombin encapsulated within double
emulsions. Furthermore, the formulations developed in chapter IV can be used in the
development of PFC double emulsions containing other water-soluble compounds in
diverse ADV applications.
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5.3 Summary of Contributions
ADV can be used to trigger the release of lipophilic or hydrophilic drugs
encapsulated within PFC double emulsions. The relationship between ADV and
IC, a phenomenon which can affect the efficacy of ADV-triggered drug release, was
also explored. Overall, the coupling of ADV-generated occlusion and ADV-triggered
drug release may afford therapeutic advantages not available with other drug release
and delivery mechanisms. The results from this dissertation are summarized below.
• ADV is a mechanism that is distinct from IC, with the ADV threshold occurring
at a lower rarefactional pressure than the IC threshold for micron-sized droplets.
• In vitro, the ADV threshold is directly correlated with the viscosity of the fluid
surrounding the droplets and inversely correlated with the degree of superheat
(for negative degrees of superheat) and droplet diameter. The ADV threshold
is independent of the gas saturation of the fluid surrounding the droplets,
the shell stabilizing the droplets, degree of superheat (for positive degrees of
superheat), PRF, and pulse width.
• The nucleus for ADV occurs within the droplet while the IC nucleus is likely
the bubble generated by ADV.
• Stable, micron-sized double emulsions can be formulated with a PFC-in-oil-in-
water or water-in-PFC-in-water structure.
• ADV can be used to significantly increase the release of oil or water-soluble
compounds encapsulated within PFC double emulsions.
• ADV of droplets adjacent to adherent cells can cause cell detachment.
• The oil layer surrounding the PFC core in a PFC-in-oil-in-water emulsion
does not significantly change the ADV threshold when compared to PFC
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only droplets that possess the same diameter as the PFC core in the double
emulsion.
• The ADV efficiency is directly correlated with droplet diameter.
• The copolymer synthesized to stabilize the primary emulsion of the water-in-
PFC-in-water emulsion possesses anticoagulative properties.
• ADV can cause inactivation of macromolecules, such as thrombin, but not low
molecular weight drugs such as chlorambucil.
5.4 Future Work
5.4.1 Optimization of PFC Loading in Emulsions
The emulsions studied in this dissertation are polydisperse in size, with coefficients
of variance ranging from 50-100% for the droplet diameters. Upon intravascular
administration, a droplet with a diameter larger than a capillary diameter can cause
an embolization. For an intravenous injection of an emulsion, large droplets will
get filtered by the pulmonary microvasculature upon entering the lungs. Figure 5.1
displays a normalized size distribution of capillary diameters in the human lung [12]
and a probability function, based on the lung capillary distribution, that a particle
of a given diameter will pass through the capillaries [13]. A particle with a diameter
equal to the average capillary diameter (6.5 µm) has a lung passage probability
equal to 0.5; correspondingly, particles whose diameters are smaller or larger than
the average capillary diameter possess lung passage probabilities greater than or less
than 0.5, respectively. Figure 5.1 also displays in vivo data from studies investigating
the effect of particulate size on lung retention. The majority of these studies were
conducted using non-degradable, non-deformable particles. Similar lung retention
studies should be completed with PFC emulsions since the droplets are deformable
and PFC excretion occurs in the lungs [14]. Lung retention studies, which are part of
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a biodistribution study, can be accomplished via the imaging of radiolabeled droplets
using positron emission tomography (PET). Initial PET studies were completed
in rats by incorporating 18F-fluorobenzoic acid hexadecyl ester into the BSA shell
of PFP droplets [15]. Another option is the incorporation of the commonly used
radiotracer 18F-fluorodeoxyglucose (18F-FDG) in the W1 phase of a W1/PFC/W2
emulsion. Preliminary PET data obtained in rats, using the double emulsion, can be
seen in Fig. 5.2.
Figure 5.1: Left: Distribution of human lung capillaries [12] and the associated proba-
bility that a particle of a given diameter will pass through the capillaries [13]. Right:
Percent of particles retained in the lungs, relative to the total number of particles
injected, one-hour after intravenous administration of particles. Five different in vivo
studies are shown: radiolabeled, polystyrene divinylbenzene microspheres in canines
[16; 17]; radiolabeled, terbutaline sulfate loaded albumin microspheres in mice [18];
radiolabeled microbubbles in mice [19]; and fluorescent polystyrene microparticles in
rats [20]. Since albumin microspheres can undergo biodegradation within the lungs
due to the presence of proteolytic enzymes [18], the percent of albumin microspheres
retained in the lungs is lower compared to non-degradable, non-deformable particles
of similar sizes [16].
The number of pulmonary vessels occluded by large (i.e. not transpulmonary)
droplets can be estimated using a representative distribution of BSA stabilized PFP
droplets that were emulsified via shaking (Fig. 5.3). These droplets were used in
chapter II and in recent in vivo, canine experiments [3], as well as in other works
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Figure 5.2: Time activity curves of standardized uptake values (SUV) for 18F-FDG
solution (left) and 18F-FDG contained in the W1 phase of a W1/PFC/W2 emulsion
(right) post tail vein injection in Fischer 344 rats. PFP was used as the PFC phase.
The rats were inoculated with 9L gliosarcoma tumors in the bilateral forearms. The
sonicated emulsion displayed a similar size distribution as seen in Fig. 5.3. Greater
uptake of 18F-FDG occurs in both tumors and the brain with the 18F-FDG solution,
compared to the W1/PFC/W2 emulsion (see Table 5.2 for integrated SUV data) due
to 18F-FDG encapsulation within the droplets. Accumulation of droplets in the liver
and minimal lung uptake are also evident.
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[1; 2; 10; 21–24]. A single droplet dose administered in the aforementioned canine
studies [3] was 108-109 droplets/kg, or approximately 3.0 × 109-1010 droplets/animal.
Therefore, using the probability function in Fig. 5.1 and the droplet distribution in
Fig. 5.3, as well as assuming a similar number and size distribution of pulmonary
capillaries in a human (70 kg) and large dog (30 kg), 4% of the droplets will remain
in the pulmonary capillaries after a single pass through the pulmonary circulation,
which is equivalent to 1.2 × 108-109 droplets. As seen in Table 5.1, there are 2.8
× 1011 capillaries in the lung. Therefore, only 0.04-0.4% of lung capillaries are
potentially occluded by a single droplet injection on first pass. Additionally, there
are 3.0 × 106-107 droplets larger than 17 µm, which as seen in Table 5.1, is the
smallest diameter of a precapillary arteriole; comparatively, there are 3.0 × 108
precapillary arterioles present in the lungs (Table 5.1). Thus, the major impact of
droplet occlusion in the lungs likely occurs at the precapillary arteriole levels since
the number of droplets that could occlude at the capillary or distribution artery level
is negligible relative to the number of respective vessels. Additionally, it becomes
clearly evident that the vaporization of transpulmonary droplets on the venous side
could cause additional pulmonary emboli due to the approximate five-fold increase
in diameter when a droplet is converted into a gas bubble [22].
Table 5.1: Blood vessels in the adult human lung [25]. By comparison, the average
number of alveoli in the adult human lung is 4.8 × 108 [26].
Type of vessel Number of vessels Diameter (µm)
Capillary 2.8 × 1011 8-16
Precapillary arteriole 3.0 × 108 17-59
Distribution artery 4.0 × 106 60-100
Hence, the minimization of large (i.e. not transpulmonary) droplets is important
to reduce the likelihood of pulmonary emboli and the pulmonary deposition of drugs
contained in large diameter, PFC double emulsions. One method to decrease the
fraction of large droplets is the use of sonication to create the PFC emulsion, as
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Figure 5.3: Number (left) and volume (right) weighted distributions of BSA stabilized
PFP droplets. The emulsions are labeled according to the emulsification method used.
The sonicated droplets possess a smaller mean diameter (1.7 µm versus 2.0 µm) and a
lower fraction of droplets that are greater than 8 µm in diameter (0.01% versus 2.2%
based on number or 4.5% versus 74.6% based on volume) compared to the shaken
droplets.
seen in Fig. 5.3. Another method is to employ centrifugal separation. However, the
minimization of small droplets, which are defined as droplets that are too small to
undergo ADV (due to a negative degree of superheat) or droplets that produce gas
bubbles that are too small to occlude a capillary, is also important for two reasons.
First, as seen in chapters II and III, the ADV threshold and efficiency scale inversely
and directly, respectively, with droplet diameter. Thus, small droplets are difficult
to vaporize, requiring increased rarefactional pressures or cavitation-driven ADV at
lower frequencies - both of which could cause vascular damage. If a small droplet
does vaporize, then occlusion is only possible if the resulting bubble coalesces with
other bubbles to form a larger bubble. Second, as will be discussed later, PFC
droplets can cause systemic bioeffects, similar to other particulates. Therefore, the
ideal PFC droplet distribution will be transpulmonary with minimal concentrations
of small or large droplets (i.e. monodisperse). Additionally, depending on the
desired effect (embolization versus drug release), the droplets should be large enough
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that upon ADV, the resulting microbubbles can cause vascular embolization at the
capillary level. It is currently unknown what droplet diameter satisfies these criteria,
though insights can be obtained from the data in Fig. 5.1.
Monodispersed droplets can be produced using microfluidic channels fabricated
from poly(dimethylsiloxane) (PDMS) [27], thereby optimizing the PFC loading for in
vivo use. Figure 5.4 displays examples of these channels while Fig. 5.5 shows droplet
distributions obtained from the microchannels. The use of monodisperse droplets
should enable tighter control of the vaporization process since the ADV threshold
and efficiency are dependent on the droplet diameter and potential minimization
of the total number of droplets needed for a given application. Additionally, the
placement of two T-junctions in series facilitates the production of double emulsions,
thereby enabling control of both the internal and external droplet diameters [28].
One consideration is the production rate of droplets from microfluidic devices, which
ranges from 10 Hz to 10 kHz [29]. For the previously mentioned canine experiment
[3], it would take a single microchannel, operating at 10 kHz, 11.5 days to produce
a single dose of 1010 droplets. Comparatively, the same number of polydisperse
droplets is obtained via shaking or sonication in 45 s. Thus, it is clearly evident that
the construction of microchannels in parallel should be completed in order to make
this droplet production method more feasible.
5.4.2 PFC Emulsion Bioeffects
Closely related to the development of ideally sized PFC emulsions, the study of
bioeffects associated with PFC emulsions used in ADV is also critically important.
Most data on PFC bioeffects originate from two medical applications: liquid
ventilation and blood substitutes [30]. The former application primarily utilizes neat
(i.e. not emulsified) PFC whereas the latter uses emulsified PFC; thus, the focus of
this discussion will be on the latter application.
Upon intravascular administration, PFC droplets undergo opsonization,
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Figure 5.4: Micrographs of microfluidic channels, fabricated in PDMS using soft
lithography, exhibiting two different flow focusing geometries. In each image, the
PFC phase flows through the central channel while an aqueous solution of surfactant
flows through two channels focused onto the PFC stream, thereby shearing droplets of
PFC. Besides PDMS, which is hydrophobic, microchannels can be made using glass,
which is hydrophilic, but can be made hydrophobic via siliconization or silanization
[28].
200 µm 
Figure 5.5: Left: Micrograph of monodispersed, BSA-stabilized PFH-in-water
droplets obtained using the microchannel in Fig. 5.4 (left). Right: Number weighted
distributions of BSA-stabilized PFH-in-water droplets produced using the microchan-
nel geometry in Fig. 5.4 (right). The channel with a 20 µm orifice produced PFH
droplets with a mean diameter of 13.2 µm and 5.8% coefficient of variance (CV) at a
rate of 290 Hz. The channel with a 35 µm orifice produced PFH droplets with a mean
diameter of 22.1 µm and 3.7% CV at a rate of 128 Hz. These distributions display
the ability of microchannels to produce monodisperse droplets (i.e. low CV), though
a smaller orifice is needed in order to produce droplets that are transpulmonary.
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phagocytosis, and eventual removal from the blood via temporary storage in the
reticuloendothelial system (RES). Figure 5.2 and Table 5.2 display the accumulation
of PFP droplets in the liver post intravenous (IV) administration. Similar to other
particulates, PFC emulsions can induce febrile-like reactions in certain species
[31]. The severity of this response, which is due to the RES activation, is directly
related to particle size [32]. Therefore, micron-sized PFC emulsion used for ADV
applications could elucidate a stronger febrile response than the submicron PFC
droplets used as blood substitutes. The febrile response associated with PFC
emulsions administered for ADV therapies has currently not been investigated.
Additionally, the minimization of particle size and narrowing of the particle size
distribution can slow the RES uptake and experienced side effects [31; 33].
Table 5.2: Integrated standardized uptake value (SUV) data (0 - 35 minutes), from




Tumor (left) 164.0 56.9
Tumor (tight) 153.5 41.2
Brain 160.9 109.6
Lungs 41.6 51.7
The stored PFCs - located primarily in the liver, spleen, and bone marrow -
are transported via lipid carriers to the lungs for eventual excretion [14]. PFP
(C5F12, 29
◦C boiling point), the most commonly used PFC in ADV applications,
is excreted completely from the lungs within 2 hours after administration of a
PFP contrast agent (i.e. microbubbles) in human subjects [34]. Compared to
PFP (288 g/mol), PFCs used as blood substitutes possess molecular weights in the
range of 460-520 g/mol [35]. As the molecular weight decreases, the vapor pressure
tends to increase, which can cause pulmonary complications. Blood substitute
studies using emulsified FX-80 (C8F16O, 3M Company), an azeotropic mixture of
perfluorobutyltetrahydrofuran, highlight some PFC bioeffects. FX-80 has a vapor
133
pressure of 0.08 bar at 37◦C, making it one of the most volatile PFCs studied as
a blood substitute; comparatively, the vapor pressure of PFP is 1.4 bar at 37◦C.
Rats given IV injections of FX-80 emulsions displayed a rapid increase in respiration
rate and bloated lungs [36; 37] as well as platelet agglutination [38]. Hyperinflated
non-collapsible lungs (HNCL) was observed in some species, such as rabbits, with
the severity of HNCL related to the vapor pressure of the administered PFC
emulsion [39], though not all species are apparently susceptible to HNCL [40; 41].
The mechanism hypothesized to cause HNCL - pulmonary gas trapping (PGT) - is
based on the formation of intra-alveolar microbubbles induced by the pulmonary
elimination of PFC [42]. The PGT mechanism is supported by results from an in
vivo study where rabbits were injected with neat perfluoroheptane (C7F16) [43]. The
inhalation of PFC vapor, from the same chemical species as the PFC emulsion, has
been found to reduce the effects of PGT in vivo [42].
The IV administration of PFP emulsions in vivo has been shown to eliminate
cardiac arrhythmias, such as premature ventricular contractions, that were observed
with intracardiac injections of droplets [3]. Figure 5.6 displays changes observed
in the arterial blood gas concentrations (pO2 and pCO2), pH, and respiration rate
in a canine that received multiple injections of PFP droplets. Similar trends were
observed in canines after the IV injection of neat PFC liquid [44]. The incidence
of HNCL in canines dosed with PFP emulsions has not been confirmed, though
suspected in a recent study [3]. Thus, in order to mitigate lung effects and changes
in blood chemistry associated with PFC emulsions, especially those containing
PFCs with high vapor pressures, it is important to minimize the dose of PFC
administered and especially the amount of PFC retained in the lungs. Therefore, the
optimization of the PFC loading in the emulsion (discussed in the previous section)
is closely linked to the minimization of systemic bioeffects associated with PFCs.
Alternatively, the use of PFC in ventilation should be attempted in future in vivo
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studies to determine if this can decrease the severity of PFC lung effects.
Figure 5.6: Arterial blood gas tensions (left) as well as arterial pH and respiration
rate (right) in a canine (26 kg) before and after IV injections of lipid-stabilized, PFP
droplets. Oxygen was used as the carrier of isoflurane, the inhaled anesthetic. A
laparatomy was performed on the animal to expose the left kidney. Each injection,
denoted by a vertical dotted line, contained 375 µL PFP and consisted of 2.4 × 1010
droplets (9.2 × 108 droplets/kg). ADV was performed in the renal artery subsequent
to each injection. During the course of the experiment, the pO2 and pH decreased
and the pCO2 and respiration rate increased in response to the injection of PFP
droplets. Respiratory acidosis was suspected in this case. Based on the emulsion
size distribution and the lung filtration function in Fig. 5.1 (left), 1% and 54% of
the droplets by number and volume, respectively, are estimated to remain in the
lung capillaries upon a single pass through the pulmonary circulation. This data is
associated with a previously published study [3].
5.4.3 ADV Bioeffects
Unlike microbubble contrast agents and their interaction with US [45], the
bioeffects related to the ADV process have not been studied extensively, especially
the mechanisms of the ADV process which cause bioeffects. Bioeffects could be
generated as a result of the various phases of the vaporization process: the droplet
displacement prior to ADV at velocities up to 20 m/s [23], the rapid consumption of
the liquid PFC during ADV, and the expansion of the resulting PFC bubble [46; 47].
Once the PFC bubble is created, it can undergo IC, a phenomenon that is known
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to produce molecular or cellular damage due to the creation of fluid jets, extreme
heating, and free radical generation upon bubble collapse. In chapter II, the IC
threshold, measured at 3.5 MHz, increased over 1 MPa in whole blood, relative to
the threshold in saline, due to the increase in solution viscosity. It is unclear whether
these in vitro results will translate directly into the in vivo case. Overall, the types
and magnitudes of bioeffects associated with ADV and ADV followed by IC should
be investigated. Additionally, it was observed in chapter III that ADV of droplets
resting on a layer of adherent cells can cause almost three-fold more cell detachment
than ADV of droplets distal to the cell layer. In both cases, the viability of the
detached cells, which could be determined using a dye exclusion (e.g. Trypan blue)
or metabolic activity (e.g. MTT) assay, was not determined. Furthermore, it should
be determined in vivo whether ADV of droplets adjacent to the endothelial lining of
a blood vessel can cause endothelial cell detachment or alter vascular permeability
via sonoporation.
Similar to results found with the cavitation of microbubble contrast agents,
ADV can generate hemolysis [48], capillary ruptures, and petechial hemorrhages.
Differences in vascular bioeffects may also occur depending on the location of ADV.
For example, the generation of ADV in the feeder artery of an organ, as has been
done in previous in vivo experiments [2; 3] could generate different effects than ADV
within the capillary bed of an organ. Vasconstriction, which has been reported in
US studies with [49; 50] and without microbubble contrast agents [51], has also been
anecdotally observed in ADV studies. The level to which vasoconstriction contributes
to the vascular embolization observed in in vivo studies is unknown. Vascular
bioeffects associated with ADV could be potentially beneficial in certain therapeutic
applications such as in blood-brain barrier disruption [52] or the sensitization of
cancer cells to radiotherapy [53] - two applications where microbubble contrast agent
disruption has shown to display synergistic properties.
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As discussed previously, the vaporization of droplets on the venous side could
cause a pulmonary embolism. Based on the PFP concentration in emulsions used
for in vivo studies [1; 3; 23], 0.25 mL PFP per mL emulsion, the volume of PFP
gas generated (assuming complete vaporization of the emulsion and the applicability
of the ideal gas law) is 35 mL per mL of emulsion at 37◦C. Deleterious respiratory
effects have been observed in vivo when ADV occurs in large veins containing a
substantial fraction of the return venous supply (ex. inferior vena cava), though
the threshold (i.e. gas volume) at which this occurs is unknown. Thus, the use
of a registered diagnostic US array and therapeutic US transducer enables the
minimization of venous ADV via precise targeting.
5.4.4 The Mechanism of Drug Release during ADV
High speed microscopy has enabled the study of individual droplets (PFC/W)
undergoing ADV [23; 46]. Similar studies focused on the ADV of PFC double
emulsions should be undertaken in order to assess the effect of the secondary phase
within the droplet. As seen in chapter III, the presence of an oil layer surrounding
the PFC core in a PFC-in-oil-in-water (PFC/O/W) emulsion did not alter the ADV
threshold significantly when correcting for the diameter of the PFC core. The ADV
threshold was not measured for the W1/PFC/W2 emulsions studied in chapter
IV. The presence of multiple W1 droplets within the PFC globule, and thus many
W1/PFC interfaces, may act as nucleation sites for ADV. It would be especially
interesting to compare the ADV threshold of two, equally sized W1/PFC/W2
droplets - one containing multiple W1 cores and the other containing a single W1
core equal in volume to the multiple cores case. The latter droplet could be made
using a microchannel system as previously described (see Fig. 5.4).
Presumably, upon ADV of a W1/PFC/W2 emulsion in vivo, the W1 phase
mixes with blood. However, the fate of the oil phase in a PFC/O/W or O/PFC/W
emulsion after ADV is unknown. Clearly, the oil phase could be released and coalesce
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into a single large droplet after ADV. However, due to the high concentration of
albumin in serum (40-50 mg/mL) [54], it is possible that smaller oil droplets are
dispersed by the ADV mechanism and subsequently stabilized by albumin. The
fragmentation of microbubble contrast agents, containing an oil layer, has been
studied using high-speed microscopy [55; 56]. These published works focus on
microbubble collapse, a distinct mechanism from ADV, rather than the release of
the oil phase. Thus, ADV studies that investigate the behavior of the oil phase
after ADV, especially in solutions that contain concentrated surfactant (e.g. serum),
should be completed. Similar studies could also determine the number and size of
gas bubbles generated from the ADV of W1/PFC/W2 droplets. A balance exists
between the ratio of the W1 and PFC phases since sufficient PFC is needed to
prevent the coalescence of the W1 and W2 phases. However, a large PFC to W1
ratio reduces the payload capacity of each droplet. The size of the resulting PFC gas
bubble produced from the ADV of a W1/PFC/W2 droplet is critical in determining
whether this gas bubble is capable of occluding blood flow within a capillary.
Closely related to the study of the ADV mechanism is the impact of ADV
on the stability of the subsequently released drug. In chapter III, ADV did not
apparently cause molecular inactivation of CHL, a small molecular weight compound
(304.2 g/mol), when released from a PFC/O/W emulsion. However, as seen in
chapter IV, ADV did cause inactivation of thrombin (∼ 36000 g/mol) when released
from a W1/PFC/W2 emulsion. The structural changes induced in thrombin after
ADV could be studied using infrared and circular dichroism spectroscopies [57].
The study could be expanded to include therapeutic molecules possessing a wide
range of molecular weights, especially macromolecules like proteins, which are more
sensitive to inactivation (i.e denaturation) using US. The monitoring of IC during the
experiment, as was done in chapter II, would enable the determination of whether
ADV alone, versus ADV followed by IC, can cause the same level or structural type
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of inactivation. To minimize the molecular effects of cavitation, Tween 80, sucrose,
and mannitol could be dissolved in the W1 phase along with the protein-based
therapeutic agent [58; 59]. Tween 80 can decrease the exposure of a solubilized
protein to gas, which can induce denaturation. Sucrose can participate in hydrogen
bonding, thereby preventing protein unfolding, and mannitol can scavenge any free
radicals generated during cavitation.
5.4.5 Shell Modifications
As discussed previously, the intravascular administration of PFC emulsions can
activate the RES and induce febrile conditions. The use of a pegylated surfactant,
which contains polyethylene glycol (PEG) conjugated to the surfactant, can reduce
these side-effects. PEG, a hydrophilic polymer, is non-toxic, safe, and has good
biocompatibility [60]. The presence of PEG chains on the droplet surface can
hinder blood protein absorption and uptake by the mononuclear phagocyte system,
thereby creating stealth particles [61]. Thus, pegylated droplets would have a longer
circulation time and greater stability against enzymatic attack and immunogenic
recognition.
Active targeting of PFC emulsions can be achieved by conjugating a ligand,
specific for a molecular target, to a surfactant or pegylated surfactant [62]. The
spatial selectivity of ADV triggered drug release would be greatly enhanced by the
ability to accumulate droplets on endothelial targets, such as vascular endothelial
growth factor receptor (VEGFR), P-selectin, or intercellular adhesion molecule-1
(ICAM-1). Extravascular receptors could also be targeted by formulating targeted
submicron droplets that, for example, could extravasate in the leaky vasculature of
tumors due to the presence of large inter-endothelial gaps. Monoclonal antibodies
have been widely used as targeting ligands in US contrast studies [19]; however, the
species-dependence, immunogenicity, cost, adhesive kinetics, and size of monoclonal
antibodies are potential drawbacks [63]. Thus, other types of ligands, such as
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peptides, have been studied [64]. One common coupling chemistry used to conjugate
a targeting ligand to the surface of a microbubble or droplet is (strept)avidin-biotin
[63], with biotinylated lipids and biotinylation kits commercially available. Despite
the flexibility and strength of this coupling, it is unlikely to be used in a clinical
setting due to the immunogenicity of (strept)avidin [65; 66]. Alternatives to
(strept)avidin-biotin coupling include the covalent attachment of a ligand via
thioether or amide bonding.
5.4.6 Further Formulation Studies
The success of an ADV application such as drug delivery or embolotherapy
relies fundamentally on the ability to vaporize PFC droplets with a high degree of
efficiency and in a controlled manner. As shown in chapter II, the ADV threshold
is inversely related to the degree of superheat for negative degrees of superheat.
Additionally, the ADV efficiency was shown to scale directly with droplet diameter in
chapter III. Therefore, the ability to modulate the vaporizability of a PFC emulsion
is critically important. A few chemical approaches are now presented.
Figure 5.7 displays the vaporization temperature (Tb) of PFP droplets, as a
function of droplet diameter (d), derived from combining the Laplace pressure and
Antoine equations (Eq. 5.1) where σ is the interfacial tension; Po is the pressure
external to the droplet; and A, B, and C are the Antoine equation parameters for
PFP. For example, at normal body temperature (37◦C), a droplet with a diameter
larger than 6.4 µm is superheated when the surface tension is 50 mN/m. Thus, for
polydisperse droplet populations as those used in chapters II-IV, not all droplets are
superheated, which is further supported by the ADV threshold and efficiency results
from chapters II and III. One option is to increase the degree of superheat of the
dispersed PFC phase, thereby lowering the diameter above which the droplets are
superheated, by using a lower boiling point fluorocarbon such as perfluorobutane
(PFB, C4F10, -1.7
◦C boiling point) or 1H-nonafluorobutane (H-PFB, C4HF9, 14
◦C
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boiling point). For example, PFB droplets with surface tensions of 30 mN/m and 50
mN/m are superheated at normal body temperature when the droplet diameters are
larger than 0.43 µm and 0.72 µm, respectively. Alternatively, mixtures of PFP, PFB,
and H-PFB can be used to adjust the ADV threshold and efficiency [4; 67]. The
second option is to use different surface active agents, which possess high critical
micelle concentrations, that significantly lower the interfacial tension between PFP
and the continuous aqueous phase. As seen in Fig. 5.7, cetyl trimethyl ammonium
bromide (CTAB) lowers the interfacial tension of PFP to 10.4 mN/m [68], which
lowers the diameter above which PFP droplets are superheated to 1.3 µm. These
strategies could be used in the development of submicron-sized PFC emulsions in
order to minimize the amount of acoustic energy needed to vaporize these droplets.
Figure 5.7: Left: The vaporization temperature of PFP droplets, as a function of
droplet diameter, for two surface tension values, 30 mN/m and 50 mN/m [8]. Right:
The surface tension tension required to stabilize PFP droplets at 37◦C as a function
of droplet diameter. At a given surface tension, droplets whose diameters lie to the
right of the line are superheated. Individual data points represent interfacial tensions
of PFP against water or phosphate buffered saline (PBS) [68]. The type of surfac-
tant used is indicated in parentheses: BSA, polyethylene oxide-co-poly-ε-caprolactone
(PEO-PCL), polyethylene oxide-co-polylactic acid (PEO-PLA), and cetyl trimethyl
ammonium bromide (CTAB). The interfacial tension was measured at a surfactant
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The stability of PFC double emulsions, with regards to decreasing the burst
release and outward diffusion of encapsulated materials, can be potentially improved
by using other shell materials. Figure 5.8 and Table 5.3 display in vitro data relating
to formulation studies, complementary to the work in chapter III, exploring the
effect of lipid versus BSA shells on the encapsulation of CHL in PFC-in-oil-in-water
emulsions. Cholesterol was incorporated into the lipid shell, thereby increasing the
shell rigidity, in an attempt to increase the stability of the emulsion, drug loading,
and drug retention [69]. Polymeric shells, such as poly(lactic-co-glycol acid) (PLGA),
have been used to generate PFC microcapsules and nanocapsules, via a modified
solvent emulsion/evaporation method, with enhanced stability relative to other types
of shells [70–72]. Currently, these capsules have been made using higher boiling point
PFCs (>56◦C), though not with PFP due to the use of methylene chloride (40◦C
boiling point) during the processing, which has a boiling point close to PFP (29◦C).
Table 5.3: The composition and characterization of CHL loading in various PFP-in-
oil-in-water emulsions. The mean (n = 3 vials) and standard deviation of each value is
presented. The CHL loading was obtained using high performance liquid chromatog-
raphy (see chapter III for method). The percent of CHL encapsulated within the
emulsion dispersed phase (i.e. encapsulation %) was determined using ultrafiltration
[73]. For the lipid stabilized emulsions, the CHL loading was substantially lower than
the BSA-stabilized droplets. Micrographs of the lipid and BSA stabilized droplets
confirmed a much thicker oil phase for the latter type of emulsion.
Emulsifier Cholesterol Mean diameter CHL Encapsulation
Type mg/mL (wt%) (µm) mg/mL pg/droplet (%)
BSA 4 0 3.06 ± 0.21 3.12 ± 0.01 7.68 ± 0.75 97.7 ± 2.3
Lipid 10 0 2.41 ± 0.08 0.67 ± 0.10 0.46 ± 0.07 98.4 ± 0.1
Lipid 10 10 2.36 ± 0.07 0.85 ± 0.09 0.61 ± 0.06 98.7 ± 0.2
Lipid 20 0 2.21 ± 0.02 0.93 ± 0.02 0.40 ± 0.01 96.5 ± 0.1
Lipid 20 10 2.27 ± 0.11 0.92 ± 0.01 0.41 ± 0.01 98.1 ± 0.5
Lipid 20 20 1.91 ± 0.05 1.15 ± 0.05 0.32 ± 0.03 97.8 ± 0.8
Lipid 20 50 1.96 ± 0.16 1.40 ± 0.04 0.27 ± 0.02 97.0 ±0.2
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Figure 5.8: Left: The cytotoxicity of different CHL emulsion formulations (PFP-in-
oil-in-water) on Chinese hamster ovary cells at various concentrations for 60 minute
exposures. The data is overlayed onto the cytotoxicity results obtained from CHL
in DMSO for 15 and 60 minute exposures (Fig. 3.6). Lipid droplets were prepared
using a modified thin-film method using different ratios of L-α-phosphatidylcholine
and cholesterol. The amount of total lipids per mL of emulsion, as well as the percent
of lipids that is cholesterol, is indicated in the parentheses. BSA stabilized droplets,
used in chapter III, are displayed as well. Right: The data from the left plot is
expressed as the fraction of CHL released, based on estimating the amount of CHL
released, from the %GI, using the CHL in DMSO data (Fig. 3.6). This drug release
is due to CHL partitioning outward from the soybean oil. For both the left and right
plots, each data point is the average of six wells from three independent experiments.
Additionally, error bars are standard deviations of the means.
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5.4.7 In vivo Demonstration
Currently, in vivo demonstrations of US-triggered drug release from PFC
emulsions has been limited to a small animal model [8; 74]. Additionally, the
aforementioned studies use submicron-sized droplets, where ADV is solely used
to release the encapsulated drug from the emulsion. This dissertation proposes
the use of ADV to simultaneously deliver an encapsulated drug and to generate
vascular embolization. Some hypothesized synergisms of ADV-triggered drug
delivery and embolization include: 1) greater drug absorption within targeted tissue
due to the prolonged residence time caused by ischemia and 2) the activation of
hypoxia-activated prodrugs (discussed later) due to extended ischemia. Additionally,
ADV could increase the ability of a released agent to penetrate further into a solid
tumor; typically, anticancer drugs only penetrate 3-5 cell diameters from a blood
vessel [75; 76]. None of these synergisms have been tested in vivo. The ability to
generate vascular occlusion has been demonstrated in vivo in both small [2] and large
animal [3] models, though the relationship between the duration of the occlusion
and other experimental parameters (injected droplet dose, acoustic exposure, etc.)
is unclear. Prior publications have shown that longer duration embolizations can be
achieved with emulsions administered intraarterially versus intravenously due to the
lack of first pass lung filtration in the former route [2; 3].
Previous studies in rats have anecdotally demonstrated that ADV can be used to
generate ischemia and hypoxia via PET imaging of 15O-H2O and
18F-fluoroazomycin
arabinoside (18F-FAZA), respectively. These studies should be continued, in order to
produce statistically significant results, using the previously mentioned radiotracers
or using orthogonal measurement techniques for ischemia (e.g. Doppler US) and
hypoxia (e.g. oxygen electrodes). The hypothesis that ADV-generated ischemia
can increase drug absorption within targeted tissue can be tested by measuring the
amount of drug present in an organ/tumor using conventional (e.g. high performance
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liquid chromatography) or radiolabeled methods. The completion of additional
PET studies, as seen in Fig. 5.2, would greatly enhance the understanding of the
biodistribution and pharmacokinetics of PFC emulsions used for ADV.
5.4.8 Delivery of Prodrugs
Areas of hypoxia, which can be found in some tumors, rarely occur in normal
tissue [77]. Unlike the chronic or diffusion-limited hypoxia occurring in tumors,
acute or perfusion-limited hypoxia can occur via the temporary arrest of blood flow,
as in the case of an ADV-generated embolization. Hypoxia can be used to activate
prodrugs, such as the chemotherapeutic agents tirapazamine or NLCQ-1 [78], which
are otherwise non-toxic in normoxic tissues. Both of the aforementioned drugs are
substrates for intracellular one-electron reductases, which convert the prodrug into
a free radical [79]. The free radical is either cytotoxic itself or can undergo further
metabolism to become cytotoxic. In normoxic tissue, the free radical reacts rapidly
with oxygen to regenerate the initial prodrug. In hypoxic tissue, the free radical
accumulates.
The release of a hypoxia-triggered prodrug, encapsulated within a PFC emulsion,
via ADV is an elegant example of the potential synergisms of ADV-triggered drug
release and embolization. ADV can be used to increase the level or homogeneity
of hypoxia within a tumor, or to generate hypoxia within another organ for the
activation of another type of prodrug. The simultaneous release of a chemical embolic
agent, as was demonstrated in chapter IV, could be used to extend the duration of
the embolization, possibly resulting in a greater level of hypoxia. Clearly, the ability
of an ADV-generated embolization to generate sufficient levels of acute hypoxia to
activate a hypoxia-triggered prodrug needs to be tested and demonstrated in vivo.
Ultimately, the clinical realizability of the proposed therapy relies on elucidating the
relationship between emulsion properties (e.g. droplet diameter, concentration, etc.),
therapeutic acoustic parameters (e.g. frequency, pulse repetition rate, etc.), and in
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vivo properties (e.g. blood vessel flow rate, vascular geometry, etc.) to the eventual
in vivo performance (e.g. ischemia, hypoxia, drug delivery, etc.).
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